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ABSTRACT
GENETIC ASSOCIATIONS WITH BORDERLINE PERSONALITY
DISORDER AND RELATED TRAITS AND BEHAVIORS
by Casey Roy Guillot
August 2012
Borderline personality disorder (BPD) and related traits and behaviors have been
linked to a number of neurotransmitter systems, including serotonin, norepinephrine,
GABA, and dopamine. Because three human single-nucleotide polymorphisms (SNPs),
COMT rs4680, GABRA2 rs279871, and SNCA rs356195, have been linked to the abovementioned neurotransmitter systems, they may be associated with BPD and related traits
and behaviors. The purpose of the current study is to examine associations of COMT
rs4680, GABRA2 rs279871, and SNCA rs356195 with both categorical and continuous
measures of BPD and with continuous measures of impulse control and self-harm in a
nonclinical sample. Healthy volunteers were categorized into genotypic and allelic
groups, and then those groups were compared in order to determine if certain genotypes
and alleles are associated with specific categorical and continuous outcomes. COMT
rs4680 was the only SNP related to both categorically and continuously measured BPD
as well as to impulse control and self-harm scores. However, results with COMT rs4680
often were suggestive of heterosis, which presents difficulty in explaining. In regard to
the other SNPs, GABRA2 rs279871 was related to BPD, impulse control, and self-harm
scores, whereas SNCA rs356195 was only related to the former two. All three SNPs
yielded some gender-specific results, which may be explained by gender differences in
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one or more of the following: COMT activity, steroid hormone and neurosteroid levels,
neurosteroid effects, regional brain structure, and DA and alpha-synuclein systems. In
conclusion, it appears that COMT, GABRA2, and SNCA may influence the development
of BPD and related traits and behaviors.
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CHAPTER I
INTRODUCTION
According to the revised 4th edition of the Diagnostic and Statistical Manual of
Mental Disorders (DSM-IV-TR) (American Psychiatric Association, 2000), biological
relatives of individuals with borderline personality disorder (BPD) are at increased risk of
being diagnosed with BPD, and impulsivity and self-harm (including non-suicidal selfinjurious behavior and suicidal behavior) are both prominent features of BPD. Looking
beyond the DSM-IV-TR, impulsivity has been prospectively associated with suicidal
behavior (Mann et al., 2009; Yen et al., 2004) and with poorer long-term outcomes in
BPD patients (Links, Mitton, & Steiner, 1990), and the early emergence of impulsivity is
suspected of playing a major role in the development of BPD (Crowell, Beauchaine, &
Linehan, 2009). Furthermore, BPD, impulsivity, non-suicidal self-injury (NSSI), and
suicidal behavior all have been shown to be moderately heritable, with heritability
estimates typically ranging from about 30% to 60% (Durrett, 2006; Mann et al., 2009),
and a recent large-scale twin-family study has indicated that a common genetic factor
accounts for a significant portion of the genetic variance in BPD and impulsivity/selfharm (Distel et al., 2010). In summary, BPD, impulsivity, and self-harm are hereditarily
influenced and appear to be related both developmentally and genetically.
Notably, a DSM-IV-TR diagnosis of BPD is categorical. In other words, an
individual meeting certain DSM-IV-TR criteria is classified as having BPD, whereas an
individual not meeting certain DSM-IV-TR criteria is classified as not having BPD. From
this perspective, BPD is a dichotomous variable: Each person either has or does not have
BPD at a specific point in time. Alternatively, BPD can be trichotomized, whereby
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individuals are classified as having a clinical BPD diagnosis (e.g., a DSM-IV-TR
diagnosis of BPD), a subclinical BPD diagnosis (i.e., falling one criterion short of a
clinical diagnosis of BPD), or no BPD diagnosis, or BPD even can be dichotomized
differently, such that individuals are classified as having a clinical/subclinical diagnosis
of BPD (i.e., having either a clinical or subclinical diagnosis of BPD) or no diagnosis of
BPD. Regardless if BPD is trichotomized or dichotomized in one way or another, it still
remains a categorical variable. Importantly, however, BPD can also be conceptualized
dimensionally. In other words, the number of BPD symptoms present in a particular
individual can be measured, and then that individual can be classified according to his or
her degree of BPD symptoms. From this perspective, BPD is a continuous variable: Each
person has a certain level of BPD symptoms at a specific point in time. Thus, BPD can be
measured both categorically and continuously.
Although BPD traditionally has been conceptualized as a categorical diagnosis,
the dimensional conceptualization of BPD has become increasingly relevant in recent
decades. Taxometric analyses have indicated that BPD is optimally measured as a
continuous variable (Edens, Marcus, & Ruiz, 2008; Trull, Widiger, & Guthrie, 1990). In
nonclinical samples, BPD symptoms have been associated with alcohol and drug use
disorders (Trull, Waudby, & Sher, 2004), and BPD features have been shown to predict
future alcohol-related problems (Stepp, Trull, & Sher, 2005). Similarly, BPD has been
shown to be one of the most commonly diagnosed personality disorders in samples of
substance abusers (Grant et al., 2008, 2004; Sutker & Allain, 2001), and a diagnosis of
BPD also has been shown to predict future onsets of substance use disorders (Walter et
al., 2009). Given the advantages of measuring BPD continuously instead of categorically
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and also that symptoms and features of BPD have been related to negative outcomes
similar to that of a diagnosis of BPD, it is important to search for genetic associations
with BPD measured both categorically and continuously.
Genetic Associations with BPD and Related Traits and Behaviors
BPD and related traits and behaviors have been linked to a number of
neurotransmitter systems, including serotonin (5-HT), norepinephrine (NE), gammaaminobutyric acid (GABA), and dopamine (DA): Serotonergic dysfunction has been
associated with BPD, impulsivity, NSSI, and suicidal behavior (Gurvits, Koenigsberg, &
Siever, 2000; Krakowski, 2003; Lester, 1995; Mann, 2002); excessive noradrenergic
activity has been implicated in heightened reactivity to stress and has been associated
with risk taking, impulsivity, and irritability (Gurvits et al., 2000; Morilak et al., 2005;
Swann, Birnbaum, Jagar, Dougherty, & Moeller, 2005); certain GABA agonists (e.g.,
valproate and carbamazepine) have been used to improve mood lability and impulsivity
in patients with BPD (Gurvits et al., 2000; Siever & Weinstein, 2009); and DA-receptor
antagonists (e.g., haloperidol and flupenthixol) have been shown to decrease impulsivity
and suicidal behavior in patients with BPD (Friedel, 2004).
Given their relationship with the above-mentioned neurotransmitter systems, the
following three human single-nucleotide polymorphisms (SNPs) may be associated with
BPD and related traits and behaviors: (1) COMT rs4680 (catechol-O-methyltransferase
gene, reference SNP 4680), also known as COMT Val158Met; (2) GABRA2 rs279871
(gamma-aminobutyric acid A receptor subunit alpha-2 gene, reference SNP 279871); and
(3) SNCA rs356195 (alpha-synuclein gene, reference SNP 356195). To elaborate,
catechol-O-methyltransferase (COMT) is an enzyme responsible for the inactivation of
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catecholamines, including DA and NE, via catalysis of their methylation (Lachman et al.,
1996; Mannisto & Kaakkola, 1999; Weinshilboum, Otterness, & Szumlanski, 1999), and
genotypic variation in COMT rs4680 has been shown to affect COMT activity in several
organs, including the brain (Chen et al., 2004; Lachman et al., 1996; Mannisto &
Kaakkola, 1999; Weinshilboum et al., 1999). Although GABA-A receptor -2 subunits
(which are encoded by GABRA2) mostly have been related to anxiety (Dixon, Rosahl, &
Stephens, 2008; Lehner et al., 2010; Low et al., 2000), they are distributed in brain
regions involved in the regulation of emotion (e.g., prefrontal cortex, amygdala, and
hippocampus) (Akbarian et al., 1995; Dixon et al., 2008; Lehner et al., 2010; Low et al.,
2000; Tian, Chen, Cross, & Edenberg, 2005) and therefore may be involved in other
emotional responses and emotionally driven behaviors, such as depression
(Vollenweider, Smith, Keist, & Rudolph, 2011) and impulsive actions motivated by
negative affective states (Villafuerte et al., 2011). Finally, -synuclein (which is encoded
by SNCA) has been shown to affect DA biosynthesis and release (Venda, Cragg,
Buchman, & Wade-Martins, 2010) and may modulate DA, 5-HT, and NE transporter
activity (Venda et al., 2010; Wersinger, Jeannotte, & Sidhu, 2006; Wersinger, Rusnak, &
Sidhu, 2006; however, also see Senior et al., 2008).
As stated previously, BPD, impulsivity, and self-harm are all moderately heritable
and appear to share genetic influence. In the following subsections, I have provided direct
and indirect evidence regarding the association of COMT rs4680, GABRA2 rs279871,
and SNCA rs356195 with BPD, impulsivity, and self-harm, although evidence pertaining
to the latter two SNPs apparently is completely lacking in some areas at this time.
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BPD and Symptoms of BPD
Of the three SNPs reviewed here, only COMT rs4680 has been examined in
relation to BPD and symptoms of BPD. One study found a relationship between COMT
rs4680 and BPD (Tadic et al., 2009), whereas another study failed to find a relationship
between COMT rs4680 and symptoms of BPD (Nemoda et al., 2010).
Impulsivity and Impulsivity-Related Traits and Behaviors
Several studies have searched for a relationship between COMT rs4680 and
impulsivity or impulsivity-related traits (e.g., novelty seeking and sensation seeking),
yielding mixed results (Benjamin et al., 2000; Chen et al., 2011; Colzato, van den
Wildenberg, van der Does, & Hommel, 2010; Demetrovics et al., 2010; Drabant et al.,
2006; Forbes et al., 2009; Golimbet, Alfimova, Gritsenko, & Ebstein, 2007; Hashimoto et
al., 2007; Hosak, Libiger, Cizek, Beranek, & Cermakova, 2006; Ishii et al., 2007; Kang,
Song, Namkoong, & Kim, 2010; Kim, Kim, Kim, Lee, & Kim, 2006; Lang, Bajbouj,
Sander, & Gallinat, 2007; Light et al., 2007; Paloyelis, Asherson, Mehta, Faraone, &
Kuntsi, 2010; Reuter & Hennig, 2005; Strobel, Lesch, Jatzke, Paetzold, & Brocke, 2003;
Tsai, Hong, Yu, & Chen, 2004; Zalsman et al., 2008). One study failed to reveal a
relationship between GABRA2 rs279871 and novelty seeking (Dick, Agrawal, et al.,
2006); however, CSF GABA levels and cortical GABA concentrations have both been
related to impulsivity in humans (Boy et al., 2011; Lee, Petty, & Coccaro, 2009), and
GABA-A agonists have been shown to increase impulsive responding in rodents (Le et
al., 2008; Oliver, Ripley, & Stephens, 2009; Thiebot, Le Bihan, Soubrie, & Simon, 1985)
and impair inhibitory control in humans (Acheson, Reynolds, Richards, & de Wit, 2006;
Deakin, Aitken, Dowson, Robbins, & Sahakian, 2004; Fillmore, Rush, Kelly, & Hays,
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2001), which is consistent with the possibility that impulsivity is regulated in part by
GABA-A receptor -2 subunits. Although SNCA rs356195 has not been specifically
related to impulsivity or impulsivity-related traits, -synuclein expression in the striatum
has been shown to influence stimulant-induced locomotion in rodents (Abeliovich et al.,
2000; Boyer & Dreyer, 2007), which is a behavior associated with impulsive responding
in rats (Dellu-Hagedorn, 2006).
Self-Harm
All of the self-harm research involving the currently reviewed SNPs has been
conducted in relation to COMT rs4680. Several studies have reported a relationship
between COMT rs4680 and suicidal behavior (Baud et al., 2007; Nolan et al., 2000; Ono,
Shirakawa, Nushida, Ueno, & Maeda, 2004; Rujescu, Giegling, Gietl, Hartmann, &
Moller, 2003), but a recent meta-analysis and a simultaneously conducted study both
failed to reveal a relationship between COMT rs4680 and suicidal behavior (Calati et al.,
2011). In addition, one study failed to find a relationship between COMT rs4680 and
self-harm scores (Silberschmidt & Sponheim, 2008). Although GABRA2 rs279871 has
not been specifically related to self-harm, participants administered the benzodiazepine
diazepam, a GABA-A agonist (Atack, 2005), have displayed increased self-aggression
(Berman, Jones, & McCloskey, 2005), and personality-disordered individuals with a
history of suicide attempts have displayed higher CSF GABA levels than personalitydisordered individuals without a history of suicide attempts (Lee et al., 2009).
Purpose of the Current Study
Most of the above-reviewed behavioral genetic studies involved the separate
examination of one of the following two outcomes: (1) potential differences in genotypic
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and allelic frequencies between groups of individuals with and without BPD, or (2)
potential differences in mean scores on dimensional measures of BPD or related traits
and behaviors between genotypic and allelic groups. The purpose of the current study is
to examine associations of COMT rs4680, GABRA2 rs279871, and SNCA rs356195
with both categorical and continuous measures of BPD and also with continuous
measures of impulse control and self-harm in a nonclinical sample. Therefore, in the
current study healthy volunteers were categorized into genotypic and allelic groups, and
then those groups were compared in order to determine if certain genotypes and alleles
are associated with specific categorical and continuous outcomes. Because several studies
have indicated that COMT and GABRA2 genotypic/allelic group differences in
impulsivity or self-harm may be gender-specific (Baud et al., 2007; Chen et al., 2011;
Golimbet et al., 2007; Lang et al., 2007; Nolan et al., 2000; Ono et al., 2004; Villafuerte
et al., 2011), separate analyses for men and women were also conducted.
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CHAPTER II
METHOD
Participants
A total of 222 participants were included in genotype testing. One participant was
excluded because of difficulty in genotyping across multiple polymorphisms, and two
participants were excluded because of only having genotyping data. In order to limit the
potentially confounding effects of population stratification, only participants who selfidentified as Caucasian were retained. Of the remaining 145 participants, 5 were
excluded because of lacking self-report data, leaving a total sample of 140 (77 male and
63 female) healthy Caucasian volunteers between the ages of 21 and 55 (M = 26.14; SD =
7.75). Participants were recruited from the university and community through fliers,
university-based e-mail announcements, and newspaper and online advertisements
requesting volunteers for a paid study ($10 per hour) on the effects of alcohol on motor
skills. All potential participants were screened by telephone interview and were excluded
if they reported that they had previously participated in alcohol-related research, had not
experienced alcohol intoxication during the past few years, were currently taking
medication with which alcohol should not be consumed, had ever experienced a
significant medical problem that was directly attributed to alcohol use, had ever been
diagnosed with schizophrenia or bipolar disorder, had experienced a depressive or
anxiety disorder in the past six months, had a psychological problem for which they were
currently engaged in treatment, or had a significant medical condition (e.g., heart, liver,
or kidney problems, diabetes, neurological disorder, or hypertension). Participants were
told that on the day of alcohol administration (which is not part of the current study but
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usually occurred within a few days to a week of it) they would be screened for alcohol
and drugs and would not be allowed to proceed if they had alcohol or any recreational
drugs in their system. During the phone screen, a cut-off score of nine on the Alcohol
Use Disorders Identification Test (AUDIT) was used to exclude potential problem
drinkers (58-92% sensitivity; Barry & Fleming, 1993; Fleming, Barry, & MacDonald,
1991; Kokotailo et al., 2004; Selin, 2006). In order to further limit the presence of
problem drinking, non-excluded individuals scoring 7 or higher on the AUDIT (68-94%
sensitivity; Barry & Fleming, 1993; Fleming et al., 1991; Kokotailo et al., 2004; Selin,
2006) were also administered the Short Michigan Alcoholism Screening Test (SMAST)
and were excluded if they scored 3 or higher (67-100% sensitivity; Nanakorn, Fukuda,
Ogimoto, Tangseree, & Treethiptikhun, 2000; Selzer, Vinokur, & van Rooijen, 1975;
Zung, 1984). Finally, weight and height were recorded for all participants, and
participants with a body mass index of 35 or greater (indicative of severe obesity) (World
Health Organization, 2003) were also excluded. The current study used data that was
collected as part of a larger research project primarily devoted to the examination of the
effects of alcohol on self-aggressive behavior. The overall study was approved by The
University of Southern Mississippi Human Subjects Protection Review Committee.
Measures
Impulse Control Measures
Barratt Impulsiveness Scale, Version 11 (BIS-11). The 30-item BIS-11 was used
to measure trait impulsivity (Patton, Stanford, & Barratt, 1995). Items are answered on a
4-point frequency scale (Rarely/Never, Occasionally, Often, Almost Always/Always), and
each item response is scored from 1 (indicative of the least impulsive response) to 4
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(indicative of the most impulsive response). BIS-11 total scores have been shown to be
higher in prison inmates in comparison to psychiatric and substance-abuse patients and
lower in college undergraduates in comparison to prison inmates and both groups of
patients (Patton et al., 1995). In the initial BIS-11 study, Cronbach’s alpha for the total
score ranged from .79 to .83 (Patton et al., 1995).
Self-Control Scale (SCS). The SCS was used to measure ability to self-regulate
(Tangney, Baumeister, & Boone, 2004). The instrument consists of 36 items answered on
a 5-point scale, with 1 representing not at all like me and 5 representing very much like
me. Each item response is scored from 1 (indicative of the least amount of self-control) to
5 (indicative of the greatest amount of self-control). Higher SCS scores have been shown
to predict greater emotional stability and less binge eating, alcohol abuse, and self- and
other-directed aggression (Tangney et al., 2004). In the initial SCS study, Cronbach’s
alpha and test-retest reliability both were .89 (Tangney et al., 2004).
Self-Harm Measures
Life History of Aggression (LHA). The 2-item LHA Self-Directed Aggression
subscale was used to assess history of self-aggression (Coccaro, Berman, & Kavoussi,
1997). The first item pertains to past frequency of self-injurious behavior, and the second
item pertains to past frequency of suicide attempts. Items are answered on a 6-point scale
ranging from 0 (never happened) to 5 (happened so many times I couldn’t give a
number). LHA Self-Directed Aggression scores have been shown to be higher in
participants diagnosed with BPD in comparison to healthy participants (Coccaro et al.,
1997). In the initial LHA study, Cronbach’s alpha and test-retest reliability for the LHA
Self-Directed Aggression subscale were .48 and .97, respectively (Coccaro et al., 1997).
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Self-Harm Inventory (SHI). The SHI was developed to assess history of
intentional self-harm and to screen for BPD (Sansone, Wiederman, & Sansone, 1998).
The instrument consists of 22 yes/no items, and yes and no responses are scored 1 and 0,
respectively, with higher scores representing a more extensive history of intentional selfharm and a greater likelihood of BPD. Cronbach’s alpha for the SHI has ranged from .80
to .90 (Sansone, Butler, Dakroub, & Pole, 2006; Sansone, Reddington, Sky, &
Wiederman, 2007; Sansone, Songer, & Sellbom, 2006).
Measures of BPD, Impulse Control, and Self-Harm
Schedule for Nonadaptive and Adaptive Personality-2 (SNAP-2). The SNAP-2
was used to assess personality traits and personality-disorder symptoms and to diagnose
DSM-IV personality disorders (Clark, Simms, Wu, & Casillas, in press). The SNAP-2
consists of 390 items comprising 12 trait scales, 3 temperament scales, and 12 diagnostic
scales. The diagnostic scales can be used to assess personality disorders dimensionally
and diagnostically based on number of symptoms and DSM-IV diagnostic criteria met,
respectively. The following four SNAP-2 scales were included in the current study:
Borderline, Impulsivity, Disinhibition, and Self-Harm. One of the Self-Harm subscales,
Suicide Proneness, was also included. Items are answered using a true/false format, and
item responses are scored 0 or 1, with 1 being indicative of a higher level of a trait or the
presence of a personality-disorder symptom and/or diagnostic criterion. In normative
samples, Cronbach’s alpha for SNAP-2 Impulsivity, Disinhibition, Self-Harm, and
Suicide Proneness ranged from .74 to .84, and test-retest reliability ranged from .76 to .93
(Clark et al., in press).
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Procedure
Written informed consent was obtained from participants prior to participation.
All measures were self-report instruments. The SNAP-2 was administered in
computerized form (Clark & Simms, 2004). All other measures were administered as
online questionnaires.
Blood was collected for genotyping using the following procedure: Latex gloves
were placed on both of the researcher’s hands. The participant’s index finger was
swabbed with an alcohol swipe on the side opposite the nail in order to reduce the chance
of local infection. An automatic fingerstick lancet device was then used to puncture the
soft side of the participant’s fingertip, slightly removed from the center. After blood from
the participant’s finger had accumulated into a tiny ball (which was eased with slight
pressure to the surrounding tissue if necessary), the blood was spotted onto 3MM
chromatography paper (Whatman, Inc., Florham Park, NJ) which was located inside a
rectangular collection form. This was repeated until three approximately 1.25 cm spots of
blood were created on the paper. The collection form was then labeled with the date, the
participant’s initials and coded number, and the name of the research assistant who
collected the blood sample. The sample was allowed a few minutes to dry before being
placed in a small plastic zip bag, which was then placed in a hanging folder inside a metal
file cabinet until all samples were ready to be mailed for genotype determination. Gloves,
alcohol swipes, and lancets were disposed of in a biohazard container.
Genotyping
Dried blood samples were analyzed at the Alcohol Research Center at Indiana
University. DNA was isolated using the HotSHOT method, which is a fast and cost-
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effective way to isolate PCR quality genomic DNA (Truett et al., 2000). In this method,
TaqMan probes are used for allelic discrimination (Applied BioSystems, Inc., Foster
City, CA). The allelic discrimination assay is a multiplexed (one primer pair/two probes
per reaction), end-point (data is collected at the end of the PCR process) assay. Each
assay mix contains two different TaqMan probes labeled with VIC or FAM fluorescent
reporter dye which bind preferentially to one of the alleles. The genotype of each sample
is determined by the fluorescence levels of the reporter dyes and is clustered on a graph
with other samples of the same genotype. Each reaction contains 5 ul of 2X TaqMan
Universal PCR Mastermix, No AmpErase UNG, 3.75 ul of water, 0.25ul of 40X Assay
Mix, and 1ul of DNA sample. Eight or eleven controls are included on each 96-well
plate: 2 no template controls, 2 or 3 heterozygous samples, and 2 or 3 of each of the
homozygous samples. Because genotyping is done by endpoint reading, thermocycling is
carried out in MJ Research PTC-200 thermocyclers. The PCR products are then analyzed
in an ABI PRISM® 7300 Sequence Detection System (SDS) instrument. SDS Software
1.3.1 converts the raw data to pure dye components and plots the results of the allelic
discrimination on a scatter plot of Allele X versus Allele Y; each genotype appears on the
graph as a cluster of points.
Data Analysis
Data analysis was conducted primarily with SPSS Statistics 17.0 for Windows.
Alpha was set at .05 for all analyses unless otherwise noted. The SNAP-2 Borderline
scale was analyzed both continuously and categorically, and the remaining continuous
measures were grouped conceptually as follows: impulse control (BIS-11, SCS, SNAP-2
Impulsivity, and SNAP-2 Disinhibition) and self-harm (LHA Self-Directed Aggression,
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SHI, SNAP-2 Self-Harm, and SNAP-2 Suicide Proneness). Two-tailed Fisher’s exact
tests were used to evaluate relationships between genotypic/allelic groups and categorical
measures (i.e., diagnoses of clinical and clinical/subclinical BPD). For one-way analyses
of variance, Levene’s test was used to test for violations of homogeneity of variance.
Although Keppel (1991, p. 127) recommended increasing the power of a similar test of
equality of variances (the Brown-Forsythe test) by setting the value of

at .25, the

sensitivity of Levene’s test has been called into question particularly for small cell sizes
(Lee, Katz, & Restori, 2010; Nordstokke & Zumbo, 2007; Zimmerman, 2004); therefore,
was set at .35 for comparisons involving any cell sizes of less than 15 and at .25 for
comparisons involving only cell sizes of 15 or more, thus increasing the power of the test
both generally and specifically for small cell sizes. The ANOVA F-test was used to test
for group differences on continuous measures when there was no evidence of unequal
variances; otherwise, the Welch test was used. For genotypic group comparisons, a post
hoc multiple comparisons procedure was employed if the omnibus test was significant or
nearly significant: Tukey’s test was used when there was no evidence of unequal
variances; otherwise, the Games-Howell test was used. Because multiple comparisons
procedures such as Tukey’s test and the Games-Howell test do not require a preliminary
test in order to be valid (Myers & Well, 2003, pp. 248-252; Ryan, 1959), the significance
or non-significance of the post hoc multiple comparisons procedure overrode that of the
omnibus test when there was a discrepancy in significance between the two tests.
Although not as worrisome as the effects of variance heterogeneity, the ANOVA F-test
has displayed some sensitivity to non-normality when variances are equal, particularly
when group sizes are unequal (Games, 1983; Harwell, Rubinstein, Hayes, & Olds, 1992;
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Levine & Dunlap, 1982; Milligan, Wong, & Thompson, 1987). Also, the Welch test has
displayed sensitivity to departures from normality when variances are unequal (Clinch &
Keselman, 1982; Harwell et al., 1992; Lix, Keselman, & Keselman, 1996). However,
non-normality under each of the preceding conditions rarely has been shown to increase
the Type I error rate higher than approximately twice the nominal

level relative to

ANOVA (Harwell et al., 1992; Levine & Dunlap, 1982; Lix et al., 1996; Milligan et al.,
1987) and the Welch test (Clinch & Keselman, 1982; Harwell et al., 1992; Lix et al.,
1996). Therefore, the Shapiro-Wilk test was used to test for non-normality when an
ANOVA or Welch test was significant or nearly significant at the standard
.10), and if the Shapiro-Wilk test was significant, then

level (p <

for the corresponding ANOVA

or Welch test (and if applicable the subsequent multiple comparisons procedure) was
adjusted to .025 in order to correct for potential Type I error inflation due to nonnormality (a strategy suggested by Keppel, 1991, p. 97). Given the frequent violations of
homogeneity of variance found in behavioral science data sets (Keselman et al., 1998),
using the Mann-Whitney and Kruskal-Wallis tests when distributions were non-normal
was not desirable because the Type I error rates of such nonparametric tests are often
substantially more inflated by concurrent violations of normality and homogeneity of
variance in comparison to parametric tests (Cribbie & Keselman, 2003; Zimmerman,
1998, 2003). In order to avoid reduced power for detecting relationships, Bonferroni
corrections were not performed, and instead the effect sizes of significant findings were
emphasized, which is a practice that has been recommended in whole or in part by a
number of researchers (Garamszegi, 2006; Kirk, 2001; Moran, 2003; Nakagawa, 2004;
O’Keefe, 2003; Perneger, 1998; Stoehr, 1999). If SPSS yielded p = .000 for a parametric
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analysis, then a more precise value for p was computed using the p-value calculator
located at http://www.graphpad.com/quickcalcs/pvalue1.cfm (GraphPad Software, 2012).
Cohen’s ds for pairwise comparisons of means were computed using the effect size
calculator retrieved from http://mason.gmu.edu/~dwilsonb/downloads/ES_Calculator.xls
(Lipsey & Wilson, 2001). Risk ratios (also known as relative risks) for binary categorical
relationships were computed using the 2 x 2 contingency table calculator located at
http://faculty.vassar.edu/lowry/odds2x2.html (Lowry, 2012). In regard to allelic group
comparisons, each homozygote group was compared to the combined group of
heterozygotes and opposing homozygotes (i.e., the combined group of individuals
sharing at least one allele) for all SNPs, which is a widely held practice in the literature.
However, the heterozygote group was compared to the combined group of homozygotes
only for COMT rs4680 and GABRA2 rs279871 because the homozygote groups were
comparable in size for both of those SNPs, whereas for SNCA rs356195 the common
homozygote group, CC participants, was about 7 times larger than the rare homozygote
group, TT participants; consequently, the mean scores for the combined group of SNCA
homozygotes (CC/TT participants) would have been severely biased in the direction of
the mean scores for the common homozygotes.
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CHAPTER III
RESULTS
Genotype Frequencies and Group Demographics
Genotype frequencies and percent distributions for COMT rs4680, GABRA2
rs279871, and SNCA rs356195 in the total sample are shown in Table 1. None of the
genotypic frequency distributions deviated significantly from expected Hardy-Weinberg
equilibrium, as ascertained with the Hardy-Weinberg equilibrium calculator located at
http://www.oege.org/software/hwe-mr-calc.shtml (Rodriguez, Gaunt, & Day, 2009).
Table 1
Genotype Frequencies and Percent Distributions in the Total Sample

Genotype Frequency (%)
___________________________________________________
SNP

Genotype 1

Genotype 2

Genotype 3

COMT rs4680

AA

AG

GG

41 (29.3)

74 (52.9)

25 (17.9)

AA

AG

GG

40 (28.6)

72 (51.4)

28 (20.0)

GABRA2 rs279871

SNCA rs356195

CC

78 (55.7)

CT

51 (36.4)

TT

11 (7.9)
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Demographics for each of the genotypic groups in the total sample are shown in
Table 2. Genotypic groups for each of the three polymorphisms did not differ
significantly in respect to gender, age, and years of education.
Table 2
Demographics for Genotypic Groups in the Total Sample

M (SD)
___________________________________________________
SNP

Group 1

Group 2

Group 3

COMT rs4680

AA

AG

GG

28/13

35/39

14/11

Age

27.10 (8.95)

25.97 (7.12)

25.08 (7.61)

Education (years)

16.72 (2.20)

16.44 (2.14)

16.68 (1.46)

GABRA2 rs279871

AA

AG

GG

Male/Female ratio

27/13

38/34

12/16

Age

26.88 (9.06)

25.34 (6.70)

27.15 (8.30)

Education (years)

17.13 (1.81)

16.28 (2.09)

16.48 (2.14)

Male/Female ratio
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Table 2 (continued).

M (SD)
___________________________________________________
SNP

Group 1

Group 2

Group 3

CC

CT

TT

44/34

28/23

5/6

Age

26.10 (7.85)

26.74 (8.05)

23.64 (5.39)

Education (years)

16.61 (2.29)

16.51 (1.75)

16.55 (1.51)

SNCA rs356195

Male/Female ratio

COMT Rs4680
SNAP-2 Borderline scale
Although an omnibus Welch test indicated that the differences in Borderline
scores between COMT genotypic groups in the total sample were only nearly significant
(adjusted

= .025), Welch statistic (2, 61.94) = 3.62, p = .032,

2

= .041, the post hoc

Games-Howell test revealed significantly higher Borderline scores (p = .022, d = .47) in
AG participants (M = 7.96, SD = 5.19) in comparison to AA participants (M = 5.74, SD =
3.44). Moreover, COMT allelic group comparisons revealed significantly lower
Borderline scores (adjusted

= .025) in AA participants (M = 5.74, SD = 3.44) relative to

GG/AG participants (M = 7.66, SD = 5.11), Welch statistic (1, 99.28) = 6.42, p = .013, d
= .41, and significantly higher Borderline scores (adjusted

= .025) in AG participants

(M = 7.96, 5.19) relative to AA/GG participants (M = 6.14, SD = 4.05), Welch statistic
(1, 134.06) = 5.29, p = .023, d = .39. Analysis by gender failed to reveal any significant
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differences in Borderline scores between COMT genotypic and allelic groups. To
summarize results for COMT thus far, AG participants displayed higher Borderline
scores, and AA participants displayed lower Borderline scores.
In regard to the relationship between COMT group membership and BPD
diagnosis, a Fisher’s exact test revealed a significant relationship between COMT
zygosity and clinical/subclinical BPD in the total sample (p = .038,

= .186, RR = 6.81),

such that COMT heterozygotes (AG participants) had a greater risk of being diagnosed
with clinical/subclinical BPD than COMT homozygotes (AA/GG participants). This
relationship was also significant in men (Fisher’s exact test, p = .043,
women (Fisher’s exact test, p = .643,

= .254) but not in

= .105). No other categorical relationships were

significant in the total sample or by gender. To summarize results for COMT in relation
to the SNAP-2 Borderline scale, AA participants reported less symptoms of BPD, and
COMT heterozygosis was related to dimensionally and diagnostically measured BPD,
such that COMT heterozygotes reported more symptoms of BPD and had a greater risk of
being diagnosed with clinical/subclinical BPD.
Impulse Control
No significant differences in impulse control were detected between COMT
genotypic and allelic groups in the total sample or in men. In women, however, an
omnibus Welch test indicated that the differences in SNAP-2 Disinhibition scores
between COMT genotypic groups were nearly significant (adjusted
statistic (2, 26.92) = 4.06, p = .029,

2

= .025), Welch

= .082, and the post hoc Games-Howell test

revealed significantly higher SNAP-2 Disinhibition scores (p = .019, d = .72) in AG
participants (M = 11.10, SD = 6.72) in comparison to GG participants (M = 6.64, SD =
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3.70). Also in women, COMT allelic group comparisons revealed significantly lower
SNAP-2 Disinhibition scores (adjusted

= .025) in GG participants (M = 6.64, SD =

3.70) relative to AA/AG participants (M = 10.63, SD = 6.22), Welch statistic (1, 24.15) =
7.97, p = .009, d = .68, nearly significantly higher BIS-11 scores in AG participants (M =
67.49, SD = 14.26) relative to AA/GG participants (M = 62.09, SD = 7.08), Welch
statistic (1, 58.69) = 3.95, p = .052, d = .45, significantly lower SCS scores (indicative of
greater impulsivity) in AG participants (M = 118.44, SD = 20.42) relative to AA/GG
participants (M = 131.09, SD = 18.31), F (1, 60) = 5.98, p = .017, d = .64, and
significantly higher SNAP-2 Disinhibition scores (adjusted

= .025) in AG participants

(M = 11.10, SD = 6.72) relative to AA/GG participants (M = 7.91, SD = 4.01), Welch
statistic (1, 59.97) = 5.48, p = .023, d = .54. To summarize results for COMT in regard to
impulse control, group differences were found only in women, with female GG
participants reporting less impulsivity on one measure and female AG participants
reporting greater impulsivity across multiple measures.
Self-Harm
In the total sample, COMT genotype was significantly related (adjusted

= .025)

to LHA Self-Directed Aggression scores, Welch statistic (2, 74.50) = 7.74, p = .001,
.037, and SNAP-2 Self-Harm scores, Welch statistic (2, 72.31) = 4.50, p = .014,

2

2

=

=

.044, and the post hoc Games-Howell tests revealed significantly higher LHA SelfDirected Aggression scores (p = .001, d = .51) in AG participants (M = .59, SD = 1.24) in
comparison to GG participants (M = .04, SD = .20) and significantly higher SNAP-2 SelfHarm scores (p = .01, d = .54) in AG participants (M = 1.74, SD = 2.05) in comparison to
GG participants (M = .72, SD = 1.21). COMT allelic group comparisons further revealed
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significantly lower LHA Self-Directed Aggression scores (adjusted

= .025) in GG

participants (M = .04, SD = .20) relative to AA/AG participants (M = .50, SD = 1.20),
Welch statistic (1, 133.38) = 14.89, p = .0002, d = .42, significantly lower SNAP-2 SelfHarm scores (adjusted

= .025) in GG participants (M = .72, SD = 1.21) relative to

AA/AG participants (M = 1.58, SD = 1.95), Welch statistic (1, 56.02) = 8.01, p = .006, d
= .47, nearly significantly higher SNAP-2 Self-Harm scores (adjusted

= .025) in AG

participants (M = 1.74, SD = 2.05) relative to AA/GG participants (M = 1.05, SD = 1.55),
Welch statistic (1, 133.15) = 5.09, p = .026, d = .38, and significantly higher SNAP-2
Suicide Proneness scores (adjusted

= .025) in AG participants (M = .86, SD = 1.34)

relative to AA/GG participants (M = .43, SD = .86), Welch statistic (1, 125.83) = 5.32, p
= .023, d = .38. To summarize the self-harm results for COMT in the total sample thus
far, GG and AG participants displayed lower and higher scores, respectively, across
multiple measures.
No significant differences in self-harm were detected between COMT genotypic
and allelic groups in women. In men, no significant differences in self-harm were
detected between COMT genotypic groups, but COMT allelic group comparisons
revealed significantly lower Suicide Proneness scores (adjusted

= .025) in AA

participants (M = .27, SD = .53) relative to GG/AG participants (M = .82, SD = 1.27),
Welch statistic (1, 70.32) = 6.83, p = .011, d = .51. Thus, COMT group differences in
self-harm in the total sample did not appear to be primarily related to either gender,
although one gender-specific difference was found in men.
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COMT rs4680 Results Summary
Of all COMT genotypes, AG was most consistently associated with BPD and
related traits and behaviors: COMT heterozygotes displayed higher SNAP-2 Borderline
scores, greater risk of being diagnosed with clinical/subclinical BPD, and higher LHA
Self-Directed Aggression, SNAP-2 Self-Harm, and SNAP-2 Suicide Proneness scores. In
addition, female heterozygotes displayed lower SCS scores (indicative of greater
impulsivity) and higher BIS-11 and SNAP-2 Disinhibition scores. In contrast to
heterozygotes, AA participants displayed lower SNAP-2 Borderline scores, and male AA
participants displayed lower SNAP-2 Suicide Proneness scores. Also, GG participants
displayed lower LHA Self-Directed Aggression and SNAP-2 Self-Harm scores, and
female GG participants displayed lower SNAP-2 Disinhibition scores. Mean scores for
COMT genotypic and allelic groups in the total sample and by gender are shown in
Tables 3-8, and frequencies for COMT zygosity by BPD clinical/subclinical diagnosis are
shown in Table 9.
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Table 3
Scores for COMT rs4680 Genotypic Groups in the Total Sample

M (SD)
_______________________________________________________

Measure
SNAP-2 BDLa

AA

AG

GG

(n = 41)

(n = 74)

(n = 25)

5.74 (3.44)*

7.96 (5.19)*

6.76 (4.85)

62.60 (11.22)

65.35 (12.08)

62.72 (7.91)

124.68 (21.49)

121.61 (19.47)

127.04 (18.12)

SNAP-2 IMPa

5.18 (3.58)

5.85 (4.02)

5.36 (3.59)

SNAP-2 DISa

10.13 (5.83)

11.61 (6.08)

9.40 (4.75)

BIS-11b
SCSb

LHA SIBb

.33 (1.12)

.59 (1.24)**

SHIc

1.90 (3.05)

3.03 (3.24)

SNAP-2 SHa

1.26 (1.72)

1.74 (2.05)*

SNAP-2 SPa

.39 (.82)

.86 (1.34)

.04 (.20)**
2.40 (1.98)
.72 (1.21)*
.48 (.92)

Note. BDL = Borderline; IMP = Impulsivity; DIS = Disinhibition; SIB = Self-Injurious Behavior; SH = Self-Harm; SP = Suicide
Proneness.
a

Three AA participants failed to complete the SNAP-2. bOne AA participant failed to complete the BIS-11, SCS, and LHA Self-

Injurious Behavior subscale. cOne AA and one AG participant failed to complete the SHI.
*different at p < .05; **different at p < .01
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Table 4
Scores for COMT rs4680 Allelic Groups in the Total Sample

Measure

SNAP-2 BDLa

M (SD)

M (SD)

AA

GG/AG

(n = 41)

(n = 99)

5.74 (3.44)*

7.66 (5.11)*

62.60 (11.22)

64.69 (11.19)

124.68 (21.49)

122.98 (19.19)

SNAP-2 IMPa

5.18 (3.58)

5.73 (3.91)

SNAP-2 DISa

10.13 (5.83)

11.05 (5.83)

.33 (1.12)

.45 (1.10)

SHIc

1.90 (3.05)

2.87 (2.97)

SNAP-2 SHa

1.26 (1.72)

1.48 (1.92)

SNAP-2 SPa

.39 (.82)

.77 (1.25)

BIS-11b
SCSb

LHA SIBb

GG

AA/AG

(n = 25)

(n = 115)

6.76 (4.85)

7.21 (4.77)

62.72 (7.91)

64.39 (11.81)

127.04 (18.12)

122.68 (20.16)

SNAP-2 IMPa

5.36 (3.59)

5.63 (3.87)

SNAP-2 DISa

9.40 (4.75)

11.11 (6.01)

SNAP-2 BDLa
BIS-11b
SCSb
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Table 4 (continued).

Measure

LHA SIBb
SHIc

M (SD)

M (SD)

GG

AA/AG

(n = 25)

(n = 115)

.04 (.20)***

.50 (1.20)***

2.40 (1.98)

SNAP-2 SHa

.72 (1.21)**

SNAP-2 SPa

.48 (.92)

SNAP-2 BDLa

2.63 (3.21)
1.58 (1.95)**
.71 (1.21)

AG

AA/GG

(n = 74)

(n = 66)

7.96 (5.19)*

6.14 (4.05)*

65.35 (12.08)

62.65 (10.01)

121.61 (19.47)

125.58 (20.15)

SNAP-2 IMPa

5.85 (4.02)

5.25 (3.56)

SNAP-2 DISa

11.61 (6.08)

9.84 (5.40)

BIS-11b
SCSb

LHA SIBb

.59 (1.24)

.22 (.89)

SHIc

3.03 (3.24)

2.09 (2.68)

SNAP-2 SHa

1.74 (2.05)†

1.05 (1.55)†

SNAP-2 SPa

.86 (1.34)*

.43 (.86)*

Note. BDL = Borderline; IMP = Impulsivity; DIS = Disinhibition; SIB = Self-Injurious Behavior; SH = Self-Harm; SP = Suicide
Proneness.

27
Table 4 (continued).
a

Three AA participants failed to complete the SNAP-2. bOne AA participant failed to complete the BIS-11, SCS, and LHA Self-

Injurious Behavior subscale. cOne AA and one AG participant failed to complete the SHI.
†

nearly significantly different; *different at p < .05; **different at p < .01; ***different at p < .001

Table 5
Scores for COMT rs4680 Genotypic Groups in Men

M (SD)
_______________________________________________________
AA

AG

GG

(n = 28)

(n = 35)

(n = 14)

5.65 (3.29)

7.66 (5.44)

8.07 (4.34)

63.04 (12.23)

62.97 (8.65)

62.79 (9.85)

122.07 (22.49)

125.14 (17.98)

123.57 (17.22)

SNAP-2 IMPa

5.08 (4.01)

5.31 (3.24)

5.93 (3.85)

SNAP-2 DISa

10.62 (6.49)

12.17 (5.33)

11.57 (4.43)

Measure
SNAP-2 BDLa
BIS-11
SCS

LHA SDA

.14 (.53)

.40 (1.01)

.07 (.27)

SHI

1.64 (2.88)

2.77 (3.27)

2.50 (2.07)

SNAP-2 SHa

1.27 (1.76)

1.69 (2.13)

.79 (1.31)

SNAP-2 SPa

.27 (.53)

.89 (1.32)

.64 (1.15)

Note. BDL = Borderline; IMP = Impulsivity; DIS = Disinhibition; SDA = Self-Directed Aggression; SH = Self-Harm; SP = Suicide
Proneness.
a

Two male AA participants failed to complete the SNAP-2.
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Table 6
Scores for COMT rs4680 Allelic Groups in Men

Measure

SNAP-2 BDLa
BIS-11
SCS

M (SD)

M (SD)

AA

GG/AG

(n = 28)

(n = 49)

5.65 (3.29)

7.78 (5.11)

63.04 (12.23)

62.92 (8.90)

122.07 (22.49)

124.69 (17.60)

SNAP-2 IMPa

5.08 (4.01)

5.49 (3.40)

SNAP-2 DISa

10.62 (6.49)

12.00 (5.05)

.14 (.53)

.31 (.87)

SHI

1.64 (2.88)

2.69 (2.96)

SNAP-2 SHa

1.27 (1.76)

1.43 (1.96)

SNAP-2 SPa

.27 (.53)*

LHA SDA

SNAP-2 BDLa
BIS-11
SCS

.82 (1.27)*

GG

AA/AG

(n = 14)

(n = 63)

8.07 (4.34)

6.80 (4.72)

62.79 (9.85)

63.00 (10.30)

123.57 (17.22)

123.78 (20.00)

SNAP-2 IMPa

5.93 (3.85)

5.21 (3.56)

SNAP-2 DISa

11.57 (4.43)

11.51 (5.86)
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Table 6 (continued).

Measure

M (SD)

M (SD)

GG

AA/AG

(n = 14)

(n = 63)

.07 (.27)

.29 (.83)

2.50 (2.07)

2.27 (3.13)

SNAP-2 SHa

.79 (1.31)

1.51 (1.97)

SNAP-2 SPa

.64 (1.15)

.62 (1.10)

LHA SDA
SHI

SNAP-2 BDLa

AG

AA/GG

(n = 35)

(n = 42)

7.66 (5.44)

6.50 (3.82)

62.97 (8.65)

62.95 (11.37)

125.14 (17.98)

122.57 (20.68)

SNAP-2 IMPa

5.31 (3.24)

5.38 (3.93)

SNAP-2 DISa

12.17 (5.33)

10.95 (5.81)

BIS-11
SCS

LHA SDA

.40 (1.01)

.12 (.45)

SHI

2.77 (3.27)

1.93 (2.65)

SNAP-2 SHa

1.69 (2.13)

1.10 (1.61)

SNAP-2 SPa

.89 (1.32)

.40 (.81)

Note. BDL = Borderline; IMP = Impulsivity; DIS = Disinhibition; SDA = Self-Directed Aggression; SH = Self-Harm; SP = Suicide
Proneness.
a

Two male AA participants failed to complete the SNAP-2.
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Table 6 (continued).

*different at p < .05

Table 7
Scores for COMT rs4680 Genotypic Groups in Women

M (SD)
_______________________________________________________
AA

AG

GG

(n = 13)

(n = 39)

(n = 11)

5.92 (3.90)

8.23 (5.00)

5.09 (5.15)

61.58 (8.83)

67.49 (14.26)

62.64 (4.88)

130.75 (18.41)

118.44 (20.42)

131.45 (19.09)

SNAP-2 IMPa

5.42 (2.54)

6.33 (4.60)

4.64 (3.26)

SNAP-2 DISa

9.08 (4.08)

11.10 (6.72)*

6.64 (3.70)*

.75 (1.87)

.77 (1.40)

.00 (.00)

SHIb

2.50 (3.45)

3.26 (3.24)

2.27 (1.95)

SNAP-2 SHa

1.25 (1.71)

1.79 (2.02)

.64 (1.12)

SNAP-2 SPa

.67 (1.23)

.85 (1.37)

.27 (.47)

Measure
SNAP-2 BDLa
BIS-11a
SCSa

LHA SDAa

Note. BDL = Borderline; IMP = Impulsivity; DIS = Disinhibition; SDA = Self-Directed Aggression; SH = Self-Harm; SP = Suicide
Proneness.
a

One female AA participant failed to complete the SNAP-2, BIS-11, SCS, and LHA Self-Directed Aggression. bOne female AA

participant and one female AG participant failed to complete the SHI.
*different at p < .05
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Table 8
Scores for COMT rs4680 Allelic Groups in Women

Measure

M (SD)

M (SD)

AA

GG/AG

(n = 13)

(n = 50)

5.92 (3.90)

7.54 (5.15)

61.58 (8.83)

66.42 (12.91)

130.75 (18.41)

121.30 (20.68)

SNAP-2 IMPa

5.42 (2.54)

5.96 (4.37)

SNAP-2 DISa

9.08 (4.08)

10.12 (6.42)

.75 (1.87)

.60 (1.28)

SHIb

2.50 (3.45)

3.04 (3.01)

SNAP-2 SHa

1.25 (1.71)

1.54 (1.91)

SNAP-2 SPa

.67 (1.23)

.72 (1.25)

SNAP-2 BDLa
BIS-11a
SCSa

LHA SDAa

GG

AA/AG

(n = 11)

(n = 52)

5.09 (5.15)

7.69 (4.83)

62.64 (4.88)

66.10 (13.34)

131.45 (19.09)

121.33 (20.48)

SNAP-2 IMPa

4.64 (3.26)

6.12 (4.20)

SNAP-2 DISa

6.64 (3.70)**

SNAP-2 BDLa
BIS-11a
SCSa

10.63 (6.22)**
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Table 8 (continued).

Measure

M (SD)

M (SD)

GG

AA/AG

(n = 11)

(n = 52)

.00 (.00)

.76 (1.51)

2.27 (1.95)

3.08 (3.27)

SNAP-2 SHa

.64 (1.12)

1.67 (1.95)

SNAP-2 SPa

.27 (.47)

.80 (1.33)

LHA SDAa
SHIb

SNAP-2 BDLa
BIS-11a
SCSa

AG

AA/GG

(n = 39)

(n = 24)

8.23 (5.00)

5.52 (4.45)

67.49 (14.26)†

62.09 (7.08)†

118.44 (20.42)*

131.09 (18.31)*

SNAP-2 IMPa

6.33 (4.60)

5.04 (2.87)

SNAP-2 DISa

11.10 (6.72)*

7.91 (4.01)*

.77 (1.40)

.39 (1.37)

SHIb

3.26 (3.24)

2.39 (2.78)

SNAP-2 SHa

1.79 (2.02)

.96 (1.46)

SNAP-2 SPa

.85 (1.37)

.48 (.95)

LHA SDAa

Note. BDL = Borderline; IMP = Impulsivity; DIS = Disinhibition; SDA = Self-Directed Aggression; SH = Self-Harm; SP = Suicide
Proneness.
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Table 8 (continued).
a

One female AA participant failed to complete the SNAP-2, BIS-11, SCS, and LHA Self-Directed Aggression. bOne female AA

participant and one female AG participant failed to complete the SHI.
†

nearly significantly different; *different at p < .05; **different at p < .01
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Table 9
COMT rs4680 Zygosity by SNAP-2 BPD Clinical/Subclinical Diagnosis (Frequencies)

Total Sample

AG

AA/GG

No diagnosis

Diagnosis

66

8

62

1

Relationship between COMT
zygosity and diagnosis
(p = .038, = .186, OR = 7.52)
Men
No diagnosis

Women
Diagnosis

No diagnosis

Diagnosis

35

4

22

1

AG
31

4
AA/AG

40

0

Relationship between COMT
zygosity and diagnosis
(p = .043, = .254)

Relationship between COMT
zygosity and diagnosis
(p = .643, = .105)

Note. Risk ratios by gender were not included because one of the cell counts for men was equal to zero.
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GABRA2 Rs279871
SNAP-2 Borderline scale
No significant differences in Borderline scores were detected between GABRA2
genotypic and allelic groups in the total sample or in women. In men, no significant
differences in Borderline scores were detected between GABRA2 genotypic groups, but
GABRA2 allelic group comparisons revealed significantly lower Borderline scores
(adjusted

= .025) in GG participants (M = 4.50, SD = 3.71) relative to AA/AG

participants (M = 7.52, SD = 4.68), Welch statistic (1, 18.39) = 6.13, p = .023, d = .66.
No significant relationships between GABRA2 group membership and BPD diagnosis
were found in the total sample or by gender. To summarize results for GABRA2 thus far,
male GG participants reported more symptoms of BPD.
Impulse Control
No significant differences in impulse control were detected between GABRA2
genotypic and allelic groups in the total sample or in men. Although an omnibus Welch
test indicated that the differences between BIS-11 scores between GABRA2 genotypic
groups in women were only nearly significant, Welch statistic (2, 27.79) = 3.29, p = .052,
2

= .076, the post hoc Games-Howell test revealed significantly higher BIS-11 scores (p

= .037, d = .60) in AG participants (M = 68.53, SD = 12.71) in comparison to GG
participants (M = 61.87, SD = 5.62). GABRA2 allelic group comparisons in women also
revealed significantly higher BIS-11 scores in AG participants (M = 68.53, SD = 12.71)
relative to AA/GG participants (M = 61.79, SD = 10.92), F (1, 60) = 4.90, p = .031, d =
.56. To summarize results for GABRA2 in regard to impulse control, group differences
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were found only in women, with female AG participants reporting greater impulsivity
and female GG participants reporting less impulsivity on one measure.
Self-Harm
No significant differences in self-harm were detected between GABRA2
genotypic and allelic groups in the total sample or in women. In men, no significant
differences in self-harm were detected between GABRA2 genotypic groups, but
GABRA2 allelic group comparisons revealed significantly lower SHI scores (adjusted
= .025) in GG participants (M = 1.08, SD = 1.31) relative to AA/AG participants (M =
2.54, SD = 3.12), Welch statistic (1, 38.78) = 7.22, p = .011, d = .50, and nearly
significantly lower SNAP-2 Suicide Proneness scores (adjusted

= .025) in GG

participants (M = .25, SD = .45) relative to AA/AG participants (M = .70, SD = 1.17),
Welch statistic (1, 44.3) = 5.17, p = .028, d = .41. To summarize results for GABRA2 in
regard to self-harm, male GG participants reported less self-harm across multiple
measures.
GABRA2 rs279871 Results Summary
Of all GABRA2 genotypes, GG was most consistently associated with BPD and
related traits and behaviors: Male GG participants displayed lower SNAP-2 Borderline,
SHI, and SNAP-2 Suicide Proneness scores, and female GG participants displayed lower
BIS-11 scores. Also, female AG participants displayed higher BIS-11 scores. Notably, all
differences between GABRA2 genotypic and allelic groups were gender-specific. Mean
scores for GABRA2 genotypic and allelic groups in the total sample and by gender are
shown in Tables 10-15.
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Table 10
Scores for GABRA2 rs279871 Genotypic Groups in the Total Sample

M (SD)
_______________________________________________________
AA

AG

GG

(n = 40)

(n = 72)

(n = 28)

7.26 (4.78)

7.59 (4.94)

5.79 (4.20)

62.83 (12.28)

66.00 (10.71)

60.85 (10.15)

122.43 (21.35)

122.61 (18.53)

127.30 (21.09)

SNAP-2 IMPa

5.00 (3.33)

6.17 (4.13)

4.89 (3.50)

SNAP-2 DISa

10.67 (5.35)

11.51 (6.04)

9.18 (5.76)

Measure
SNAP-2 BDLa
BIS-11b
SCSb

LHA SDAb

.23 (.66)

.58 (1.32)

.26 (.94)

SHIc

2.93 (3.56)

2.72 (2.96)

1.74 (2.11)

SNAP-2 SHa

1.67 (2.11)

1.20 (1.54)

1.64 (2.23)

SNAP-2 SPa

.74 (1.16)

.59 (1.06)

.75 (1.40)

Note. BDL = Borderline; IMP = Impulsivity; DIS = Disinhibition; SDA = Self-Directed Aggression; SH = Self-Harm; SP = Suicide
Proneness.
a

One AA participant and two AG participants failed to complete the SNAP-2. bOne GG participant failed to complete the BIS-11,

SCS, and LHA Self-Directed Aggression. cOne AG and one GG participant failed to complete the SHI.
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Table 11
Scores for GABRA2 rs279871 Allelic Groups in the Total Sample

Measure

M (SD)

M (SD)

AA

GG/AG

(n = 40)

(n = 100)

7.26 (4.78)

7.07 (4.79)

62.83 (12.28)

64.60 (10.76)

122.43 (21.35)

123.89 (19.26)

SNAP-2 IMPa

5.00 (3.33)

5.81 (3.98)

SNAP-2 DISa

10.67 (5.35)

10.85 (6.03)

SNAP-2 BDLa
BIS-11b
SCSb

LHA SDAb

.23 (.66)

.49 (1.23)

SHIc

2.93 (3.56)

2.45 (2.77)

SNAP-2 SHa

1.67 (2.11)

1.33 (1.76)

SNAP-2 SPa

.74 (1.16)

.63 (1.16)

GG

AA/AG

(n = 28)

(n = 112)

5.79 (4.20)

7.47 (4.86)

60.85 (10.15)

64.87 (11.34)

127.30 (21.09)

122.54 (19.49)

SNAP-2 IMPa

4.89 (3.50)

5.75 (3.89)

SNAP-2 DISa

9.18 (5.76)

11.21 (5.79)

SNAP-2 BDLa
BIS-11b
SCSb
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Table 11 (continued).

Measure

M (SD)

M (SD)

GG

AA/AG

(n = 28)

(n = 112)

.26 (.94)

.46 (1.14)

SHIc

1.74 (2.11)

2.79 (3.17)

SNAP-2 SHa

1.64 (2.23)

1.37 (1.77)

SNAP-2 SPa

.75 (1.40)

.64 (1.09)

LHA SDAb

SNAP-2 BDLa

AG

AA/GG

(n = 72)

(n = 68)

7.59 (4.94)

6.64 (4.58)

66.00 (10.71)

62.03 (11.43)

122.61 (18.53)

124.39 (21.22)

SNAP-2 IMPa

6.17 (4.13)

4.96 (3.38)

SNAP-2 DISa

11.51 (6.04)

10.04 (5.53)

BIS-11b
SCSb

LHA SDAb

.58 (1.32)

.24 (.78)

SHIc

2.72 (2.96)

2.45 (3.09)

SNAP-2 SHa

1.20 (1.54)

1.66 (2.14)

SNAP-2 SPa

.59 (1.06)

.75 (1.26)

Note. BDL = Borderline; IMP = Impulsivity; DIS = Disinhibition; SDA = Self-Directed Aggression; SH = Self-Harm; SP = Suicide
Proneness.
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Table 11 (continued).
a

One AA participant and two AG participants failed to complete the SNAP-2. bOne GG participant failed to complete the BIS-11,

SCS, and LHA Self-Directed Aggression. cOne AG and one GG participant failed to complete the SHI.

Table 12
Scores for GABRA2 rs279871 Genotypic Groups in Men

M (SD)
_______________________________________________________
AA

AG

GG

(n = 27)

(n = 38)

(n = 12)

7.31 (4.98)

7.68 (4.52)

4.50 (3.71)

63.37 (10.89)

63.74 (8.05)

59.58 (14.15)

122.19 (19.00)

123.74 (17.03)

127.25 (27.48)

SNAP-2 IMPa

5.04 (3.19)

5.59 (3.59)

5.25 (4.62)

SNAP-2 DISa

10.77 (5.00)

12.49 (5.65)

10.17 (6.52)

Measure
SNAP-2 BDLa
BIS-11
SCS

LHA SDA

.15 (.46)

.39 (1.00)

.00 (.00)

SHI

2.96 (3.89)

2.24 (2.45)

1.08 (1.31)

SNAP-2 SHa

1.62 (2.19)

1.16 (1.52)

1.50 (2.24)

SNAP-2 SPa

.85 (1.32)

.59 (1.07)

.25 (.45)

Note. BDL = Borderline; IMP = Impulsivity; DIS = Disinhibition; SDA = Self-Directed Aggression; SH = Self-Harm; SP = Suicide
Proneness.
a

One male AA participant and one male AG participant failed to complete the SNAP-2.
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Table 13
Scores for GABRA2 rs279871 Allelic Groups in Men

Measure

SNAP-2 BDLa
BIS-11
SCS

M (SD)

M (SD)

AA

GG/AG

(n = 27)

(n = 50)

7.31 (4.98)

6.90 (4.51)

63.37 (10.89)

62.74 (9.85)

122.19 (19.00)

124.58 (19.77)

SNAP-2 IMPa

5.04 (3.19)

5.51 (3.82)

SNAP-2 DISa

10.77 (5.00)

11.92 (5.89)

.15 (.46)

.30 (.89)

SHI

2.96 (3.89)

1.96 (2.28)

SNAP-2 SHa

1.62 (2.19)

1.24 (1.70)

SNAP-2 SPa

.85 (1.32)

.51 (.96)

LHA SDA

SNAP-2 BDLa
BIS-11
SCS

GG

AA/AG

(n = 12)

(n = 65)

4.50 (3.71)*
59.58 (14.15)
127.25 (27.48)

7.52 (4.68)*
63.58 (9.25)
123.09 (17.75)

SNAP-2 IMPa

5.25 (4.62)

5.37 (3.42)

SNAP-2 DISa

10.17 (6.52)

11.78 (5.42)
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Table 13 (continued).

Measure

M (SD)

M (SD)

GG

AA/AG

(n = 12)

(n = 65)

.00 (.00)

.29 (.82)

SHI

1.08 (1.31)*

2.54 (3.12)*

SNAP-2 SHa

1.50 (2.24)

1.35 (1.82)

SNAP-2 SPa

.25 (.45)†

LHA SDA

SNAP-2 BDLa
BIS-11
SCS

.70 (1.17)†

AG

AA/GG

(n = 38)

(n = 39)

7.68 (4.52)

6.42 (4.75)

63.74 (8.05)

62.21 (11.92)

123.74 (17.03)

123.74 (21.71)

SNAP-2 IMPa

5.59 (3.59)

5.11 (3.64)

SNAP-2 DISa

12.49 (5.65)

10.58 (5.44)

LHA SDA

.39 (1.00)

.10 (.38)

SHI

2.24 (2.45)

2.38 (3.41)

SNAP-2 SHa

1.16 (1.52)

1.58 (2.18)

SNAP-2 SPa

.59 (1.07)

.66 (1.15)

Note. BDL = Borderline; IMP = Impulsivity; DIS = Disinhibition; SDA = Self-Directed Aggression; SH = Self-Harm; SP = Suicide
Proneness.
a

One male AA participant and one male AG participant failed to complete the SNAP-2.
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Table 13 (continued).
†

nearly significantly different; *different at p < .05

Table 14
Scores for GABRA2 rs279871 Genotypic Groups in Women

M (SD)
_______________________________________________________

Measure
SNAP-2 BDLa
BIS-11b
SCSb

AA

AG

GG

(n = 13)

(n = 34)

(n = 16)

7.15 (4.56)

7.48 (5.44)

6.75 (4.41)

61.69 (15.21)

68.53 (12.71)*

61.87 (5.62)*

122.92 (26.42)

121.35 (20.25)

127.33 (15.24)

SNAP-2 IMPa

4.92 (3.73)

6.82 (4.62)

4.63 (2.50)

SNAP-2 DISa

10.46 (6.21)

10.42 (6.36)

8.44 (5.22)

.38 (.96)

.79 (1.59)

.47 (1.25)

SHIc

2.85 (2.88)

3.27 (3.40)

2.27 (2.49)

SNAP-2 SHa

1.77 (2.01)

1.24 (1.58)

1.75 (2.30)

SNAP-2 SPa

.54 (.78)

.58 (1.06)

1.13 (1.75)

LHA SDAb

Note. BDL = Borderline; IMP = Impulsivity; DIS = Disinhibition; SDA = Self-Directed Aggression; SH = Self-Harm; SP = Suicide
Proneness.
a

One female AG participant failed to complete the SNAP-2. bOne female GG participant failed to complete the BIS-11, SCS, and LHA

Self-Directed Aggression. cOne female AG participant and one female GG participant failed to complete the SHI.
*different at p < .05
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Table 15
Scores for GABRA2 rs279871 Allelic Groups in Women

Measure

M (SD)

M (SD)

AA

GG/AG

(n = 13)

(n = 50)

7.15 (4.56)

7.24 (5.09)

61.69 (15.21)

66.49 (11.40)

122.92 (26.42)

123.18 (18.91)

SNAP-2 IMPa

4.92 (3.73)

6.10 (4.16)

SNAP-2 DISa

10.46 (6.21)

9.78 (6.03)

.38 (.96)

.69 (1.49)

SHIc

2.85 (2.88)

2.96 (3.16)

SNAP-2 SHa

1.77 (2.01)

1.41 (1.84)

SNAP-2 SPa

.54 (.78)

.76 (1.33)

SNAP-2 BDLa
BIS-11b
SCSb

LHA SDAb

GG

AA/AG

(n = 16)

(n = 47)

6.75 (4.41)

7.39 (5.16)

61.87 (5.62)

66.64 (13.63)

127.33 (15.24)

121.79 (21.84)

SNAP-2 IMPa

4.63 (2.50)

6.28 (4.43)

SNAP-2 DISa

8.44 (5.22)

10.43 (6.25)

SNAP-2 BDLa
BIS-11b
SCSb
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Table 15 (continued).

Measure

M (SD)

M (SD)

GG

AA/AG

(n = 16)

(n = 47)

.47 (1.25)

.68 (1.45)

SHIc

2.27 (2.49)

3.15 (3.24)

SNAP-2 SHa

1.75 (2.30)

1.39 (1.71)

SNAP-2 SPa

1.13 (1.75)

.57 (.98)

AG

AA/GG

(n = 34)

(n = 29)

7.48 (5.44)

6.93 (4.40)

68.53 (12.71)*

61.79 (10.92)*

LHA SDAb

SNAP-2 BDLa
BIS-11b
SCSb

121.35 (20.25)

125.29 (20.88)

SNAP-2 IMPa

6.82 (4.62)

4.76 (3.06)

SNAP-2 DISa

10.42 (6.36)

9.34 (5.67)

.79 (1.59)

.43 (1.10)

SHIc

3.27 (3.40)

2.54 (2.65)

SNAP-2 SHa

1.24 (1.58)

1.76 (2.13)

SNAP-2 SPa

.58 (1.06)

.86 (1.41)

LHA SDAb

Note. BDL = Borderline; IMP = Impulsivity; DIS = Disinhibition; SDA = Self-Directed Aggression; SH = Self-Harm; SP = Suicide
Proneness.
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Table 15 (continued).
a

One female AG participant failed to complete the SNAP-2. bOne female GG participant failed to complete the BIS-11, SCS, and LHA

Self-Directed Aggression. cOne female AG participant and one female GG participant failed to complete the SHI.
*different at p < .05
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SNCA Rs356195
SNAP-2 Borderline scale
No significant differences in Borderline scores were detected between SNCA
genotypic and allelic groups in the total sample or in men. In women, an omnibus Welch
test indicated that SNCA genotype was significantly related (adjusted
Borderline scores, Welch statistic (2, 13.30) = 6.13, p = .013,

2

= .025) to

= .172, but the post hoc

Games-Howell test only revealed nearly significantly higher Borderline scores in TT
participants (M = 13.33, SD = 4.59) in comparison to CC participants (M = 6.24, SD =
3.61, p = .026, d = 1.89) and CT participants (M = 7.04, SD = 5.70, p = .045, d = 1.14).
Consistent with previous findings, however, SNCA allelic group comparisons revealed
significantly higher Borderline scores (adjusted

= .025) in female TT participants (M =

13.33, SD = 4.59) relative to female CC/CT participants (M = 6.57, SD = 4.55), F (1, 60)
= 11.94, p = .001, d = 1.48. No significant relationships between SNCA group
membership and BPD diagnosis were found in the total sample or by gender. To
summarize results for SNCA thus far, the only significant finding in relation to BPD was
in women, with female TT participants reporting more symptoms of BPD.
Impulse Control
In the total sample, no significant differences in impulse control were detected
between SNCA genotypic groups, but SNCA allelic group comparisons revealed
significantly higher BIS-11 scores in CT/TT participants (M = 66.39, SD = 12.30)
relative to CC participants (M = 62.28, SD = 9.97), Welch statistic (1, 114.02) = 4.50, p =
.036, d = .37, significantly lower SCS scores (indicative of greater impulsivity) in CT/TT
participants (M = 119.28, SD = 20.11) relative to CC participants (M = 126.74, SD =

48
19.08), F (1, 137) = 5.00, p = .027, d = .38, nearly significantly higher SNAP-2
Impulsivity scores (adjusted

= .025) in CT/TT participants (M = 6.38, SD = 4.39)

relative to CC participants (M = 4.95, SD = 3.18), Welch statistic (1, 103.68) = 4.55, p =
.035, d = .38, nearly significantly higher SNAP-2 Disinhibition scores (adjusted

= .025)

in CT/TT participants (M = 11.97, SD = 6.20) relative to CC participants (M = 9.88, SD =
5.38), Welch statistic (1, 117.16) = 4.27, p = .041, d = .36, and nearly significantly higher
BIS-11 scores in TT participants (M = 70.18, SD = 12.97) relative to CC/CT participants
(M = 63.56, SD = 10.94), F (1, 137) = 3.61, p = .060, d = .60. To summarize results for
SNCA in the total sample, CT/TT participants reported greater impulsivity on all impulse
control measures, and TT participants reported greater impulsivity on one measure.
In men, no significant differences were detected between SNCA genotypic
groups, but SNCA allelic group comparisons revealed significantly lower SCS scores
(indicative of greater impulsivity) in CT/TT participants (M = 117.85, SD = 18.56)
relative to CC participants (M = 128.16, SD = 19.05), F (1, 75) = 5.64, p = .020, d = .55.
Similar to men, no significant differences in impulse control were detected between
SNCA genotypic groups in women, but SNCA allelic group comparisons revealed nearly
significantly higher BIS-11 scores in CT/TT participants (M = 68.75, SD = 13.55)
relative to CC participants (M = 62.79, SD = 10.66), Welch statistic (1, 50.76) = 3.58, p =
.064, d = .50. Thus, SNCA group differences in impulsivity in the total sample did not
appear to be primarily related to either gender overall, although differences on certain
measures appeared to be more gender-specific.
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Self-Harm
No significant differences in self-harm were detected across SNCA genotypic and
allelic groups in the total sample or by gender.
SNCA rs356195 Results Summary
Although not as clear as with the other two SNPs, a pattern for SNCA did emerge
in regard to BPD and related traits and behaviors: Female TT participants displayed
higher SNAP-2 Borderline scores, and participants possessing at least one T allele
(CT/TT participants) reported greater impulsivity on all impulse control measures, with
some evidence to suggest that possessing two T alleles may confer additional risk of
greater impulsivity (higher BIS-11 scores in TT participants). Therefore, T seemed to be
a risk allele for SNCA in relation to impulsivity generally and BPD symptoms
specifically in women. Mean scores for SNCA genotypic and allelic groups in the total
sample and by gender are shown in Tables 16-21.
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Table 16
Scores for SNCA rs356195 Genotypic Groups in the Total Sample

M (SD)
_______________________________________________________
CC
Measure

CT

TT

(n = 78)

(n = 51)

(n = 11)

6.48 (4.19)

7.68 (5.14)

9.30 (6.45)

62.28 (9.97)

65.56 (12.13)

70.18 (12.97)

126.74 (19.08)

121.04 (18.57)

111.27 (25.52)

SNAP-2 IMPa

4.95 (3.18)

6.46 (4.50)

6.00 (4.03)

SNAP-2 DISa

9.88 (5.38)

11.90 (6.49)

12.30 (4.76)

.40 (1.14)

.38 (1.03)

.73 (1.19)

SHIc

2.31 (3.04)

2.94 (3.09)

3.00 (2.49)

SNAP-2 SHa

1.22 (1.69)

1.52 (1.93)

2.50 (2.55)

SNAP-2 SPa

.62 (1.06)

.62 (1.21)

1.20 (1.55)

SNAP-2 BDLa
BIS-11b
SCSb

LHA SDAb

Note. BDL = Borderline; IMP = Impulsivity; DIS = Disinhibition; SDA = Self-Directed Aggression; SH = Self-Harm; SP = Suicide
Proneness.
a

One CC, one CT, and one TT participant failed to complete the SNAP-2. bOne CT participant failed to complete the BIS-11, SCS,

and LHA Self-Directed Aggression. cTwo CT participants failed to complete the SHI.
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Table 17
Scores for SNCA rs356195 Allelic Groups in the Total Sample

Measure

M (SD)

M (SD)

CC

CT/TT

(n = 78)

(n = 62)

6.48 (4.19)

7.95 (5.35)

62.28 (9.97)*

66.39 (12.30)*

126.74 (19.08)*

119.28 (20.11)*

SNAP-2 IMPa

4.95 (3.18)†

6.38 (4.39)†

SNAP-2 DISa

9.88 (5.38)†

11.97 (6.20)†

SNAP-2 BDLa
BIS-11b
SCSb

LHA SDAb

.40 (1.14)

.44 (1.06)

SHIc

2.31 (3.04)

2.95 (2.97)

SNAP-2 SHa

1.22 (1.69)

1.68 (2.05)

SNAP-2 SPa

.62 (1.06)

.72 (1.28)

SNAP-2 BDLa
BIS-11b
SCSb

TT

CC/CT

(n = 11)

(n = 129)

9.30 (6.45)

6.95 (4.60)

70.18 (12.97)†

63.56 (10.94)†

111.27 (25.52)

124.52 (19.01)

SNAP-2 IMPa

6.00 (4.03)

5.54 (3.81)

SNAP-2 DISa

12.30 (4.76)

10.68 (5.90)
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Table 17 (continued).

Measure

M (SD)

M (SD)

TT

CC/CT

(n = 11)

(n = 129)

.73 (1.19)

.39 (1.10)

SHIc

3.00 (2.49)

2.55 (3.06)

SNAP-2 SHa

2.50 (2.55)

1.34 (1.79)

SNAP-2 SPa

1.20 (1.55)

.62 (1.12)

LHA SDAb

Note. BDL = Borderline; IMP = Impulsivity; DIS = Disinhibition; SDA = Self-Directed Aggression; SH = Self-Harm; SP = Suicide
Proneness.
a

One CC, one CT, and one TT participant failed to complete the SNAP-2. bOne CT participant failed to complete the BIS-11, SCS,

and LHA Self-Directed Aggression. cTwo CT participants failed to complete the SHI.
†

nearly significantly different; *different at p < .05

Table 18
Scores for SNCA rs356195 Genotypic Groups in Men

M (SD)
_______________________________________________________
CC
Measure
SNAP-2 BDLa
BIS-11
SCS

CT

TT

(n = 44)

(n = 28)

(n = 5)

6.66 (4.61)

8.22 (4.64)

3.25 (2.87)

61.89 (9.51)

63.61 (10.03)

68.80 (15.88)

128.16 (19.05)

118.68 (17.23)

113.20 (26.87)
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Table 18 (continued).

M (SD)
_______________________________________________________
CC
Measure

CT

TT

(n = 44)

(n = 28)

(n = 5)

SNAP-2 IMPa

4.84 (3.26)

6.33 (4.17)

4.25 (1.71)

SNAP-2 DISa

10.75 (5.67)

12.96 (5.63)

10.25 (2.50)

.23 (.74)

.29 (.85)

.20 (.45)

SHI

2.16 (3.16)

2.75 (2.84)

1.20 (1.10)

SNAP-2 SHa

1.27 (1.84)

1.59 (2.08)

1.00 (.82)

SNAP-2 SPa

.57 (1.02)

.70 (1.26)

.75 (.96)

LHA SDA

Note. BDL = Borderline; IMP = Impulsivity; DIS = Disinhibition; SDA = Self-Directed Aggression; SH = Self-Harm; SP = Suicide
Proneness.
a

One male CT participant and one male TT participant failed to complete the SNAP-2.

Table 19
Scores for SNCA rs356195 Allelic Groups in Men

Measure

SNAP-2 BDLa
BIS-11

M (SD)

M (SD)

CC

CT/TT

(n = 44)

(n = 33)

6.66 (4.61)

7.58 (4.73)

61.89 (9.51)

64.39 (10.95)
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Table 19 (continued).

Measure

M (SD)

M (SD)

CC

CT/TT

(n = 44)

(n = 33)

128.16 (19.05)*

117.85 (18.56)*

SNAP-2 IMPa

4.84 (3.26)

6.06 (3.98)

SNAP-2 DISa

10.75 (5.67)

12.61 (5.38)

.23 (.74)

.27 (.80)

SHI

2.16 (3.16)

2.52 (2.69)

SNAP-2 SHa

1.27 (1.84)

1.52 (1.96)

SNAP-2 SPa

.57 (1.02)

.71 (1.22)

SCS

LHA SDA

SNAP-2 BDLa
BIS-11
SCS

TT

CC/CT

(n = 5)

(n = 72)

3.25 (2.87)

7.25 (4.65)

68.80 (15.88)

62.56 (9.68)

113.20 (26.87)

124.47 (18.83)

SNAP-2 IMPa

4.25 (1.71)

5.41 (3.68)

SNAP-2 DISa

10.25 (2.50)

11.59 (5.72)

.20 (.45)

.25 (.78)

SHI

1.20 (1.10)

2.39 (3.03)

SNAP-2 SHa

1.00 (.82)

1.39 (1.92)

LHA SDA
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Table 19 (continued).

Measure

SNAP-2 SPa

M (SD)

M (SD)

TT

CC/CT

(n = 5)

(n = 72)

.75 (.96)

.62 (1.11)

Note. BDL = Borderline; IMP = Impulsivity; DIS = Disinhibition; SDA = Self-Directed Aggression; SH = Self-Harm; SP = Suicide
Proneness.
a

One male CT participant and one male TT participant failed to complete the SNAP-2.

*different at p < .05

Table 20
Scores for SNCA rs356195 Genotypic Groups in Women

M (SD)
_______________________________________________________
CC
Measure
SNAP-2 BDLa

(n = 34)

CT
(n = 23)

TT
(n = 6)

6.24 (3.61)†

7.04 (5.70)†

13.33 (4.59)†

62.79 (10.66)

68.05 (14.22)

71.33 (11.45)

124.91 (19.24)

124.05 (20.15)

109.67 (26.79)

SNAP-2 IMPa

5.09 (3.13)

6.61 (4.94)

7.17 (4.83)

SNAP-2 DISa

8.73 (4.80)

10.65 (7.31)

13.67 (5.61)

.62 (1.50)

.50 (1.23)

1.17 (1.47)

BIS-11b
SCSb

LHA SDAb
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Table 20 (continued).

M (SD)
_______________________________________________________
CC
Measure

CT

TT

(n = 34)

(n = 23)

(n = 6)

SHIc

2.50 (2.92)

3.19 (3.44)

4.50 (2.35)

SNAP-2 SHa

1.15 (1.50)

1.43 (1.78)

3.50 (2.88)

SNAP-2 SPa

.70 (1.13)

.52 (1.16)

1.50 (1.87)

Note. BDL = Borderline; IMP = Impulsivity; DIS = Disinhibition; SDA = Self-Directed Aggression; SH = Self-Harm; SP = Suicide
Proneness.
a

One female CC participant failed to complete the SNAP-2. bOne female CT participant failed to complete the BIS-11, SCS, and LHA

Self-Directed Aggression. cTwo female CT participants failed to complete the SHI.
†

Scores for female TT participants were nearly significantly higher than those for female CC and CT participants.

Table 21
Scores for SNCA rs356195 Allelic Groups in Women

Measure

SNAP-2 BDLa
BIS-11b
SCSb
SNAP-2 IMPa

M (SD)

M (SD)

CC

CT/TT

(n = 34)

(n = 29)

6.24 (3.61)

8.34 (6.00)

62.79 (10.66)†

68.75 (13.55)†

124.91 (19.24)

120.96 (22.01)

5.09 (3.13)

6.72 (4.84)
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Table 21 (continued).

Measure

SNAP-2 DISa

M (SD)

M (SD)

CC

CT/TT

(n = 34)

(n = 29)

8.73 (4.80)

11.28 (7.01)

.62 (1.50)

.64 (1.28)

SHIc

2.50 (2.92)

3.48 (3.24)

SNAP-2 SHa

1.15 (1.50)

1.86 (2.17)

SNAP-2 SPa

.70 (1.13)

.72 (1.36)

LHA SDAb

TT

CC/CT

(n = 6)

(n = 57)

SNAP-2 BDLa

13.33 (4.59)**

BIS-11b

71.33 (11.45)

64.86 (12.33)

109.67 (26.79)

124.57 (19.42)

SNAP-2 IMPa

7.17 (4.83)

5.71 (4.00)

SNAP-2 DISa

13.67 (5.61)

9.52 (5.98)

LHA SDAb

1.17 (1.47)

.57 (1.39)

SHIc

4.50 (2.35)

2.76 (3.12)

SNAP-2 SHa

3.50 (2.88)

1.27 (1.61)

SNAP-2 SPa

1.50 (1.87)

.63 (1.14)

SCSb

6.57 (4.55)**

Note. BDL = Borderline; IMP = Impulsivity; DIS = Disinhibition; SDA = Self-Directed Aggression; SH = Self-Harm; SP = Suicide
Proneness.
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Table 21 (continued).
a

One female CC participant failed to complete the SNAP-2. bOne female CT participant failed to complete the BIS-11, SCS, and LHA

Self-Directed Aggression. cTwo female CT participants failed to complete the SHI.
†

nearly significantly different; **different at p < .01
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CHAPTER IV
DISCUSSION
COMT Rs4680
COMT rs4680 was the only SNP related to both categorically and continuously
measured BPD: Heterozygotes (AG participants) displayed higher SNAP-2 Borderline
scores (d = .39) and were nearly 7 times as likely to be diagnosed with clinical/subclinical
BPD ( = .186, RR = 6.81) relative to homozygotes (AA/GG participants). Although the
relationship between COMT zygosity and clinical/subclinical BPD was also significant in
men ( = .254) but not in women ( = .105), effect sizes for men and women as well as
for the total sample were comparable according to the effect size standards set forth by
Cohen (1988/2009, pp. 223-225), in which

= .1 is a “small” effect and

= .3 is a

“medium” effect. Additionally, Met homozygotes (AA participants) displayed lower
SNAP-2 Borderline scores than heterozygotes (d = .47) and Val (G) carriers (d = .41).
According to the effect size standards recommended by Cohen (1988/2009, pp. 25-26),
d = .2 is a “small” effect; d = .5 is a “medium” effect; and d = .8 is a large effect.
Therefore, all of the above-mentioned effects are rather small, albeit some are almost
medium. Contrary to the current study, Tadic et al. (2009) found a higher percentage of
COMT Met/Met (AA) genotype in Caucasian BPD patients compared to healthy
participants, and Nemoda et al. (2010) failed to find a relationship between COMT
rs4680 and BPD symptoms in a sample of Caucasian psychiatric inpatients or in an
ethnically heterogeneous sample of at-risk young adults. It is noteworthy, however, that
the current study was the first study to examine the relationship between COMT rs4680
and BPD in an ethnically homogenous nonclinical sample. Thus, differences in study
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design (i.e., case-control vs. cross-sectional) and sample selection (i.e., psychiatric/at-risk
vs. nonclinical and also ethnically heterogeneous vs. ethnically homogeneous) may help
to explain why results have been inconsistent across studies.
COMT rs4680 was related to impulse control only in women, which yielded
several medium effects: Female Val homozygotes (GG participants) displayed lower
SNAP-2 Disinhibition scores than female heterozygotes (d = .72) and Met (A) carriers
(d = .68), and female heterozygotes also displayed higher BIS-11 (d = .45) and SNAP-2
Disinhibition scores (d = .54) and lower SCS scores (indicative of greater impulsivity;
d = .64) than female homozygotes. Most studies that have examined the relationship
between COMT rs4680 and impulsivity or impulsivity-related traits have included a
measure of novelty seeking, and none of those studies have been entirely consistent with
the current results. Eight studies conducted with Caucasian, Asian, or Israeli participants
failed to find a relationship between COMT rs4680 and novelty seeking (Benjamin et al.,
2000; Drabant et al., 2006; Hashimoto et al., 2007; Ishii et al., 2007; Kim et al., 2006;
Light et al., 2007; Reuter & Hennig, 2005; Strobel et al., 2003), including those studies
which separately analyzed men and women (Ishii et al., 2007; Kim et al., 2006; Reuter &
Hennig, 2005), and four studies found patterns that were inconsistent with the current
study, such as Met homozygotes displaying the highest novelty seeking scores
(Demetrovics et al., 2010; Golimbet et al., 2007), Val homozygotes displaying higher
novelty seeking scores than heterozygotes (Tsai et al., 2004), and Val homozygotes
displaying lower novelty seeking scores than Met homozygotes in men but not in women
(Chen et al., 2011). One study did find that Val homozygotes had lower novelty seeking
scores than Met carriers, but the sample size was small (N = 37); and approximately
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three-fourths of participants were men (Hosak et al., 2006). Similar to studies that have
examined the relationship between COMT rs4680 and novelty seeking, one study failed
to find a relationship between COMT rs4680 and sensation seeking in Koreans (Kang et
al., 2010), and another study conducted with participants of German descent found that
female Val homozygotes displayed significantly higher sensation seeking scores than
female heterozygotes and female Met homozygotes (Lang et al., 2007). Of greatest
relevance to the current study, no previous study has found a relationship between COMT
rs4680 and trait impulsivity (Colzato et al., 2010; Forbes et al., 2009; Paloyelis et al.,
2010; Zalsman et al., 2008). However, none of those four studies separately analyzed
males and females, and each study had further limitations or differences relative to the
current study: Zalsman et al. (2008) administered an earlier version of the Barratt
Impulsiveness Scale to currently depressed patients; Forbes et al. (2009) used a smaller
sample (N = 86) that was somewhat ethnically heterogeneous (~90% white); Colzato et
al. (2010) administered the Dickman Impulsivity Inventory and only compared Val
homozygotes to Met carriers; and Paloyelis et al. (2010) administered the adolescent
version of the BIS-11 to a smaller sample (N = 68) of males between the ages of 11 and
20 (M = 15.42). Although the current study was not entirely consistent with any of the
past studies that examined the relationship between COMT rs4680 and impulsivity or
impulsivity-related traits, the current study was the first study to examine the relationship
between COMT rs4680 and impulsivity in women. Thus, past studies that have searched
for a relationship between COMT rs4680 and impulsivity may have been precluded from
obtaining significant results because of their use of mixed-gender or male samples.
Notably, the Val/Val genotype has been associated with higher levels of COMT activity,
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which presumably leads to greater inactivation of DA and NE in the brain (Chen et al.,
2004; Lachman et al., 1996; Matsumoto et al., 2003). Consistent with female Val
homozygotes displaying lower SNAP-2 Disinhibition scores in the current study,
substances that increase DA or NE activity have been shown to increase impulsivity in
patients with Parkinson’s disease and in healthy participants, respectively (Cools, Barker,
Sahakian, & Robbins, 2003; Swann et al., 2005).
COMT rs4680 was related to self-harm in the total sample and in men, which
yielded several small-to-medium effects: COMT Val homozygotes displayed lower LHA
Self-Directed Aggression (d = .51) and SNAP-2 Self-Harm scores (d = .54) than
heterozygotes and also lower LHA Self-Directed Aggression (d = .42) and SNAP-2 SelfHarm scores (d = .47) than Met carriers, and heterozygotes further displayed higher
SNAP-2 Self-Harm (d = .38) and SNAP-2 Suicide Proneness scores (d = .38) than
homozygotes. In addition, male Met homozygotes displayed lower Suicide Proneness
scores (d = .51) than male Val carriers. Contrary to the current study, a recent metaanalysis (which included ten studies) and a simultaneously conducted study both failed to
reveal a relationship between COMT rs4680 and suicidal behavior (Calati et al., 2011),
and two other studies also were inconsistent with the current study: Massat et al. (2005)
found a higher percentage of Val/Val genotype in bipolar disorder patients with a history
of suicide attempt compared to patients who had never attempted suicide, and
Silberschmidt and Sponheim (2008) failed to find a relationship between COMT rs4680
and self-harm scores. However, all thirteen previous studies used samples of psychiatric
patients or participants likely having a current psychiatric disorder (Baud et al., 2007; De
Luca et al., 2006; De Luca, Tharmalingam, Sicard, & Kennedy, 2005; Liou, Tsai, Hong,
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Wang, & Lai, 2001; Nolan et al., 2000; Ohara, Nagai, Suzuki, & Ohara, 1998; Ono et al.,
2004; Rujescu et al., 2003; Russ, Lachman, Kashdan, Saito, & Bajmakovic-Kacila, 2000;
Zalsman et al., 2008). Although Ono et al. (2004) did not provide information concerning
the psychiatric status of their participants, it can be safely assumed that the large majority
of suicide completers in their study also had a psychiatric disorder given that past
research has indicated that approximately 90% of suicide completers had a psychiatric
disorder at the time of suicide (Mann, 2002). Furthermore, only three of the thirteen
previous studies (Russ et al., 2000; Silberschmidt & Sponheim, 2008; Zalsman et al.,
2008) administered a continuous measure of self-harm or suicidal ideation instead of or
in addition to ascertaining categorically-defined history of suicidal behavior (i.e., suicide
or attempted suicide). In contrast to previous studies, in the current study healthy
volunteers were administered a number of continuous self-harm measures representative
of both suicidal behavior and less extreme forms of self-harm. For example, the LHA
Self-Directed Aggression subscale consists of two items pertaining to frequency of past
self-injurious behavior and suicide attempts; the SHI consists of 22 items pertaining to
history of intentional self-harm, including suicidal and self-injurious behavior as well as
self-destructive thoughts and behaviors; the SNAP-2 Self-Harm scale consists of 16 items
pertaining to poor self-esteem, pessimistic thoughts, history of suicidal and self-injurious
behavior, and thoughts of suicide and self-injury; and lastly the SNAP-2 Suicide
Proneness subscale consists of 9 items pertaining to thoughts of suicide and self-injury
and history of suicidal and self-injurious behavior (i.e., the SNAP-2 Self-Harm scale
minus the items related to poor self-esteem and pessimistic thoughts). Therefore,
differences in sample selection (i.e., clinical vs. nonclinical) and sensitivity of self-harm
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measurement (i.e., measurement of suicidal behavior vs. continuous measurement of a
wider range of self-harm) may help to explain the inconsistency across studies.
Although COMT is involved in the inactivation of DA and NE, COMT activity in
the brain has mostly been related to its ability to modulate DA neurotransmission in the
prefrontal cortex (Matsumoto et al., 2003), and genotypic variation in COMT rs4680 has
been shown to influence COMT activity in the human brain, with Val homozygotes
displaying greater COMT activity in the dorsolateral prefrontal cortex (DLPFC) than
heterozygotes and Met homozygotes (Chen et al., 2004). Thus, in regard to the current
findings in which Val homozygotes scored lower than heterozygotes or Met carriers,
those findings may be explained (at least in part) by differences in DA neurotransmission
in the DLPFC resulting from genotypically driven variation in COMT activity.
Importantly, however, COMT activity may also indirectly affect the tonic and phasic
release of DA in subcortical regions as a consequence of its aforementioned modulatory
effect on cortical DA neurotransmission (Bilder, Volavka, Lachman, & Grace, 2004).
Furthermore, COMT activity across various regions of the human brain as a function of
COMT genotype has not been studied, and prior research involving other tissues (e.g.,
blood and liver) evidenced greater genotypically driven variation in COMT activity than
that observed in the DLPFC, with distinctly low, medium, and high levels of COMT
activity among Met/Met, Val/Met, and Val/Val genotypes, respectively (Lachman et al.,
1996). Therefore, a number of the current findings (including those in which Met
homozygotes scored lower than heterozygotes or Val carriers) may be explained by
differences in DA neurotransmission in some other brain region besides the DLPFC
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(perhaps even in another prefrontal region) as a result of genotypically driven variation in
COMT activity.
Gender-specific results with COMT rs4680 may be explained by gender
differences in COMT activity and dopaminergic function, both of which may be a
consequence of the effects of estrogen. Men have displayed greater COMT activity than
women (Chen et al., 2004; Xie, Ho, & Ramsden, 1999), which may be the result of
higher estrogen levels in women leading to decreased COMT activity (Overpeck, Colson,
Hohmann, Applestine, & Reilly, 1978; Xie et al., 1999). In addition, men and women
have displayed differences in brain DA levels and receptor binding as well as differences
in amphetamine-induced positive affect and regional DA release, which may be related to
the effects of estrogen on dopaminergic function (Cantuti-Castelvetri et al., 2007;
Haaxma et al., 2007; Munro et al., 2006; Riccardi et al., 2011, 2006).
Admittedly, one set of findings in the current study presents greater difficulty in
explaining: COMT heterozygotes frequently differed from homozygotes (i.e., Val and
Met homozygotes combined). Previously mentioned research indicated that Val and Met
homozygosity are at opposite ends in terms of level of COMT activity, and thus one
would not expect heterozygotes to differ from homozygotes if self-reported differences
are assumed to be the result of differences in DA neurotransmission in a particular brain
region secondary to genotypically driven variation in COMT activity. However, this set
of findings is consistent with the phenomenon known as molecular heterosis. Molecular
heterosis occurs when individuals heterozygous for a genetic polymorphism display
significantly more or less of an effect for a continuous or dichotomous trait than
homozygotes, with positive heterosis indicating a greater effect and negative heterosis
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indicating a lesser effect in heterozygotes (Comings & MacMurray, 2000). In the current
study, results for COMT rs4680 were suggestive of positive heterosis for the following
measures: SNAP-2 clinical/subclinical BPD diagnosis and SNAP-2 Borderline, SelfHarm, and Suicide Proneness scores in the total sample, and BIS-11, SCS, and SNAP-2
Disinhibition scores in women. Similar to the current study, one study reported a higher
percentage of COMT heterozygosity (Val/Met genotype) in methamphetamine abusers
who relapsed in comparison to abusers who remained abstinent after one year, suggestive
of positive heterosis (Hosak, Horacek, Beranek, & Cermakova, 2007). In contrast to the
current study, a recent meta-analysis of the relationship between COMT rs4680 and
schizophrenia revealed a protective effect for heterozygosity, suggestive of negative
heterosis (Costas et al., 2011). Negative COMT heterosis in relation to mental disorder or
symptoms of mental disorder could be explained by an inverted U-shaped response
curve, in which heterozygosity is associated with an optimal level of neurotransmitter
function (Comings & MacMurray, 2000; Costas et al., 2011). Although positive COMT
heterosis in relation to mental disorder or symptoms of mental disorder is not as readily
explainable, one potential explanation is that COMT activity below a certain threshold
may induce compensatory changes in the brain, and another potential explanation is that
the trait in question may be excited or inhibited by multiple brain regions which are
differentially affected by variation in COMT activity (Gogos et al., 1998). One final
potential explanation is that COMT activity may also play a major role in modulating NE
neurotransmission in the hippocampus (Matsumoto et al., 2003), which may interact with
the effects of COMT activity on DA neurotransmission in the hippocampus and other
parts of the brain. Consistent with this potential explanation and some other previously
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mentioned ones, neuroimaging studies of BPD patients have revealed abnormalities in the
frontolimbic network, including the hippocampus, DLPFC, and other prefrontal regions
(Leichsenring, Leibing, Kruse, New, & Leweke, 2011; Schmahl & Bremner, 2006).
GABRA2 Rs279871
GABRA2 rs279871 was related to BPD only in men, which yielded one medium
effect: Male G homozygotes displayed lower SNAP-2 Borderline scores than male Aallele carriers (d = .66). This is the first study to report a relationship between GABRA2
and BPD symptoms. Interestingly, however, some previous studies have positively
associated the A allele of GABRA2 rs279871 with conduct disorder symptoms (Dick,
Bierut, et al., 2006), alcohol dependence (Dick, Bierut, et al., 2006; Edenberg et al., 2004;
Philibert et al., 2009), and other drug dependence (Agrawal et al., 2006; Dick, Bierut, et
al., 2006; Philibert et al., 2009), and another study using two large subsamples (n = 1105
and n = 816) reported a higher percentage of antisocial personality disorder (ASPD) in
participants with the AA genotype relative to G-carriers in both samples (Dick, Agrawal,
et al., 2006). Because those studies did not separately analyze males and females, it is
possible that the relationships they detected were more specific to males but were strong
enough to yield significant results using mixed-gender samples, especially given that
previous studies genotyped hundreds or even thousands of individuals. Based on current
and past results, it appears that the A allele of GABRA2 rs279871 may be a risk factor
for the development of personality- and substance-related psychopathology, particularly
in males.
GABRA2 rs279871 was related to impulse control only in women, which yielded
two medium effects: Female heterozygotes (AG participants) displayed higher BIS-11
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scores than female GG participants (d = .60) and homozygotes (d = .56). Although no
previous studies have examined the relationship between GABRA2 rs279871 and
impulsivity, one study failed to reveal a relationship between GABRA2 rs279871 and
novelty seeking (Dick, Agrawal, et al., 2006); however, that particular study only
compared AA participants to G-allele carriers and did not separately analyze men and
women. Consistent with the possibility that variation in GABRA2 influences the
development of impulsivity, CSF GABA levels and cortical GABA concentrations have
both been related to impulsivity in humans (Boy et al., 2011; Lee et al., 2009), and
GABA-A agonists have been shown to increase impulsive responding in rodents (Le et
al., 2008; Oliver et al., 2009; Thiebot et al., 1985) and impair inhibitory control in
humans (Acheson et al., 2006; Deakin et al., 2004; Fillmore et al., 2001). Also, two other
GABRA2 SNPs, GABRA2 rs279826 and GABRA2 rs279858, have been associated with
impulsiveness scores, particularly in women (Villafuerte et al., 2011). Therefore, it is
possible that variation in GABRA2 influences the development of impulsivity,
particularly in women.
GABRA2 rs279871 was related to self-harm only in men, which yielded two
small-to-medium effects: Male G homozygotes displayed lower SNAP-2 Suicide
Proneness (d = .41) and SHI (d = .50) scores than A-allele carriers. Although no previous
studies have examined the relationship between GABRA2 and self-harm, participants
administered diazepam, a GABA-A agonist (Atack, 2005), have displayed increased selfaggression (Berman et al., 2005), and personality-disordered individuals with a history of
suicide attempts have displayed higher CSF GABA levels than personality-disordered
individuals without a history of suicide attempts (Lee et al., 2009). Also as previously
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mentioned, past studies have positively associated the A allele of GABRA2 rs279871
with conduct disorder symptoms (Dick, Bierut, et al., 2006), alcohol dependence
(Edenberg et al., 2004; Dick, Bierut, et al., 2006; Philibert et al., 2009), and other drug
dependence (Agrawal et al., 2006; Dick, Bierut, et al., 2006; Philibert et al., 2009) and
have associated the AA genotype with ASPD (Dick, Agrawal, et al., 2006). Thus, the A
allele of GABRA2 rs279871 may be a risk factor for the development of personality- and
substance-related psychopathology, including self-harm, again particularly in males.
Although GABA-A receptor -2 subunits mostly have been related to anxiety
(Dixon et al., 2008; Lehner et al., 2010; Low et al., 2000), they may be involved in other
emotional responses and emotionally driven behaviors, such as depression (Vollenweider
et al., 2011) and impulsive actions motivated by negative affective states (Villafuerte et
al., 2011). As stated previously, GABA-A receptor -2 subunits are distributed
throughout brain regions involved in the regulation of emotion (e.g., prefrontal cortex,
amygdala, and hippocampus) (Akbarian et al., 1995; Dixon et al., 2008; Lehner et al.,
2010; Low et al., 2000; Tian et al., 2005), and neuroimaging studies of BPD patients have
revealed abnormalities in the frontolimbic network, including the prefrontal cortex,
amygdala, and hippocampus (Leichsenring et al., 2011; Schmahl & Bremner, 2006).
According to the DSM-IV-TR, BPD is characterized in part by mood reactivity (e.g.,
intense intermittent states of depression, anxiety, or irritability) and impairments in
impulse control, possibly including substance abuse (American Psychiatric Association,
2000). Given all of the preceding information, it is reasonable to suspect that GABRA2
may influence a diversity of emotional responses and emotionally driven behaviors and
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by extension may influence the development of BPD and related traits and behaviors,
such as impulsivity and self-harm.
Intriguingly, all of the current findings in relation to GABRA2 rs279871 were
gender-specific. Such findings may be explained by gender differences in the levels of
steroid hormones (e.g., progesterone and testosterone) and neurosteroids as well as by
gender differences in the effects of neurosteroids and in the structure of brain regions
containing GABA-A receptor -2 subunits. Neurosteroids, such as allopregnanolone (a
neuroactive metabolite of progesterone), androstanediol (a neuroactive metabolite of
testosterone), dehydroepiandrosterone (DHEA), and its sulfated metabolite, DHEA
sulfate (DHEAS), can act as positive or negative allosteric modulators of GABA-A
receptor function (Engel & Grant, 2001; Reddy, 2010). Furthermore, allopregnanolone,
DHEA, and DHEAS can also enhance or attenuate GABA-A receptor-mediated
inhibition of 5-HT neuronal activity (Gartside, Griffith, Kaura, & Ingram, 2010; Kaura,
Ingram, Gartside, Young, & Judge, 2007). In regard to gender differences, circulating
levels of progesterone and allopregnanolone have been shown to be higher in women
during the luteal phase than in men (Genazzani et al., 1998; Overpeck et al., 1978); blood
levels of testosterone and androstanediol have been shown to be higher in men than in
women (Overpeck et al., 1978; Strickland & Apland, 1977; Wudy, Wachter, Homoki, &
Teller, 1996); blood-serum concentrations of DHEA have been shown to be higher in
women than in men (Genazzani et al., 1998); and serum levels of DHEAS have been
shown to be higher in males in comparison to females across all age groups between the
ages of 17 and 69 years, with the largest difference in DHEAS levels occurring between
the ages of 20 and 29 years (Young, Skibinski, Mason, & James, 1999). Also, one study
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revealed sex differences in the anxiogenic effects of acute exposure to progesterone and
allopregnanolone in rats (Gulinello & Smith, 2003), raising the possibility that gender
differences in the effects of neurosteroids may occur in humans. Finally, neuroimaging
has revealed gender differences (relative to cerebrum size) in the sizes of the amygdala
and prefrontal regions (Goldstein et al., 2001), which are brain regions containing
GABA-A receptor -2 subunits (Akbarian et al., 1995; Dixon et al., 2008; Lehner et al.,
2010; Low et al., 2000; Tian et al., 2005).
In the current study, BIS-11 results for GABRA2 rs279871 were suggestive of
positive heterosis in women. Perhaps related to impulsivity, one previous GABRA2
rs279871 study reported a higher proportion of AG genotype and a lower proportion of
GG genotype in polysubstance abusers compared to control participants (Drgon,
D’Addario, & Uhl, 2006). Similar to one aforementioned potential explanation for
positive COMT heterosis in relation to symptoms of mental disorder, positive GABRA2
heterosis in relation to impulsivity may be explained by impulsive behavior being
excited or inhibited by multiple brain regions which are differentially affected by
genetically influenced variation in GABA-A -2 subunit receptor function.
SNCA Rs356195
SNCA rs356195 was related to BPD only in women, which yielded three large
effects: Female T homozygotes displayed higher SNAP-2 Borderline scores than female
C homozygotes (d = 1.89), heterozygotes (d = 1.14), and C-allele carriers (d = 1.48). This
is the first study to report a relationship between SNCA and BPD symptoms. SNCA
rs356195 was also related to impulsivity across all four measures of impulse control,
which yielded several small-to-medium effects: T-allele carriers displayed lower SCS
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scores (indicative of greater impulsivity; d = .38) and higher BIS-11 (d = .37), SNAP-2
Impulsivity (d = .38), and SNAP-2 Disinhibition scores (d = .36) than C homozygotes,
and T homozygotes displayed higher BIS-11 scores than C-allele carriers (d = .60). In
addition, gender-specific analyses revealed higher BIS-11 scores in female T-allele
carriers in comparison to female C homozygotes (d = .50) and lower SCS scores
(indicative of greater impulsivity) in male T-allele carriers in comparison to male C
homozygotes (d = .55). Although no previous studies have examined the relationship
between SNCA and impulsivity or impulsivity-related traits, -synuclein expression in
the striatum has been shown to influence stimulant-induced locomotion in rodents
(Abeliovich et al., 2000; Boyer & Dreyer, 2007), which is a behavior associated with
impulsive responding in rats (Dellu-Hagedorn, 2006). Of potential relevance to the
current findings, the C allele of SNCA rs356195 has been negatively associated with
history of alcohol craving (Foroud et al., 2007), and blood -synuclein levels have been
positively correlated with alcohol and cocaine craving scores (Bonsch et al., 2004; Mash
et al., 2008). Notably, alcohol-related psychopathology has been related both to
dimensionally and diagnostically measured BPD: More specifically, BPD symptoms have
been positively correlated with alcohol use disorder in a nonclinical sample of 395 young
adults (Trull et al., 2004), and BPD is estimated to be the most commonly diagnosed
lifetime personality disorder among individuals with a 12-month alcohol use disorder in
the general population (Grant et al., 2008, 2004). Based on past and present findings, it is
tempting to speculate that the C allele of SNCA 356195 may be a protective factor
against the development of impulsivity, which in turn may serve as a protective factor
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against the development of disorders involving poor impulse control, such as BPD and
substance-related disorders.
SNCA rs356195 was not significantly related to self-harm in the total sample or
by gender. One possible explanation is that there is no relationship between SNCA
rs356195 and self-harm. However, another possibility is that the current study lacked
adequate power to detect a relationship between SNCA rs356195 and self-harm. A visual
examination of Tables 16 and 20 appears to support the latter possibility: T homozygotes
displayed the highest scores across all four self-harm measures in the total sample and
particularly in women. Greater self-harm in female T homozygotes also would have been
consistent with the current study’s finding of greater BPD symptoms in female T
homozygotes. Thus, it would be premature to conclude that SNCA rs356195 is probably
not related to self-harm, especially given that this is the first study to examine the
relationship between SNCA and self-harm.
Although -synuclein may modulate DA, 5-HT, and NE transporter activity
(Venda et al., 2010; Wersinger, Jeannotte, et al., 2006; Wersinger, Rusnak, et al., 2006;
however, also see Senior et al., 2008), it most clearly has been shown to reduce DA
biosynthesis and release (Venda et al., 2010). Consistent with a role for -synuclein (and
thus SNCA) in the etiology of BPD and related traits and behaviors, DA blockers have
been shown to decrease impulsivity and suicidal behavior in patients with BPD (Friedel,
2004), and L-DOPA (which increases DA activity) has been shown to increase
impulsivity in patients with Parkinson’s disease (Cools et al., 2003). Moreover, DA
receptors are found in the prefrontal cortex, amygdala, and hippocampus (Matsumoto et
al., 2003; Wise, 2009), which are all brain regions where -synuclein is highly expressed
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(Clayton & George, 1998; Jakes, Spillantini, & Goedert, 1994; Venda et al., 2010;
Ziolkowska et al., 2005) and where abnormalities have been detected in BPD patients
(Leichsenring et al., 2011; Schmahl & Bremner, 2006). Therefore, SNCA may influence
the development of BPD and related traits and behaviors via the effects of -synuclein on
DA biosynthesis and release in the prefrontal cortex, amygdala, and/or hippocampus.
In regard to gender-specific results with SNCA rs356195, such findings may be
explained by gender differences in the DA and -synuclein systems. As stated
previously, men and women have displayed differences in brain DA levels and receptor
binding as well as differences in amphetamine-induced positive affect and regional DA
release, which may be related to the effects of estrogen on dopaminergic function
(Cantuti-Castelvetri et al., 2007; Haaxma et al., 2007; Munro et al., 2006; Riccardi et al.,
2011, 2006). Lewy bodies, which are intracellular inclusions primarily found in brain
neurons and mostly composed of -synuclein, are characteristic of neurodegenerative
disorders such as Parkinson’s disease and dementia with Lewy bodies (Clayton &
George, 1998; Nelson et al., 2010; Venda et al., 2010; Ziolkowska et al., 2005), and men
are at greater risk of developing Parkinson’s disease and neocortical and limbic Lewy
bodies and have displayed greater -synuclein expression in dopaminergic neurons
(Cantuti-Castelvetri et al., 2007; Haaxma et al., 2007; Nelson et al., 2010).
Limitations
In a nationally representative sample, the majority of individuals diagnosed with
lifetime BPD also had at least one 12-month substance use, mood, or anxiety disorder
(Grant et al., 2008), and in large nonclinical samples BPD symptoms or features have
been positively correlated with anxiety, mood, and alcohol and drug use disorders (Trull,
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1995; Trull et al., 2004). Thus, one limitation is that, as part of a larger research project,
the current study discouraged recent drug use and also excluded potential problem
drinkers and individuals who reported experiencing a lifetime bipolar disorder or a recent
depressive or anxiety disorder, which may have made it more difficult to detect genetic
associations as a result of restricting the number of individuals diagnosed with BPD as
well as the range of BPD, impulse control, and self-harm scores. For example, although
one SNP (COMT rs4680) was associated with a diagnosis of clinical/subclinical BPD,
the current study failed to detect an association between any of the SNPs and a diagnosis
of clinical BPD; however, only 2.9% of participants (n = 4) received a diagnosis of
clinical BPD in the total sample (83.3% of which was composed of individuals between
the ages of 21 and 29). In comparison, 9.3% of individuals between the ages of 20 and 29
in a nationally representative sample received a diagnosis of lifetime BPD (Grant et al.,
2008). Nevertheless, the use of a nonclinical sample free of a number of psychiatric and
medical disorders and current exposure to psychiatric medications is also a strength
because it removes several factors that may confound genetic associations with BPD.
Another limitation of the current study is its sample size. The effect size of any single
SNP tends to be rather small, and detecting such an effect may require a sample size in
the hundreds. In the current study (which used a total sample of 140 participants), only
effect sizes that were approximately mid-range between small and medium or larger were
significant in the total sample, and only effect sizes that were about medium-to-large
were significant when analyzed by gender. Sample size also would not have been
sufficient to search for SNP interactions because cell sizes for several genotypic pairings
in the total sample would have been less than 5 (with some cell sizes as small as 1).
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Another limitation of the current study is its reliance on self-report instruments. It would
have been interesting and perhaps more compelling if self-report measures of impulse
control and self-harm had been supplemented with behavioral measures of impulsivity
and self-aggression. Another limitation is that the current study only included individuals
who self-identified as Caucasian. Although this practice was employed in order to limit
the potentially confounding effects of population stratification, it also limits the ability to
generalize current results beyond that of Caucasians. One final limitation of the current
study, which is a limitation common to genetic association studies, is that genetic
variation in particular SNPs cannot be inferred to be causative but only suggestive of a
causative role for the genes in which those SNPs partially represent. COMT rs4680 has
been shown to be a functional SNP (i.e., has been shown to influence physiological
differences in the body), but it is still possible that genotypes or alleles of all three SNPs
are not independent of genotypes or alleles of other SNPs (i.e., that all three SNPs are in
linkage disequilibrium with other SNPs) and that it is those other SNPs which play a
more direct role in the development of BPD and related traits and behaviors.
Future Directions
In addition to attempting to replicate current results, future studies should search
for associations between the current SNPs and behavioral measures of impulsivity and
self-aggression. Future research should also attempt to expand the current results by
examining SNP-SNP and SNP-environment interactions in relation to BPD, impulse
control, and self-harm. Specifically related to COMT rs4680, it may be fruitful to
genotype and administer behavioral measures of impulsivity and self-aggression to
individuals acutely exposed to placebo or a centrally active COMT inhibitor, such as
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tolcapone (Apud et al., 2007). In relation to SNCA rs356195 (and other SNPs of SNCA),
it may be useful to measure -synuclein expression (i.e., protein or mRNA levels) in the
blood combined with genotyping and the administration of tests or tasks. Given the
possible role of GABA-A receptor -2 subunits in the regulation of emotion, the
literature is in need of studies involving GABRA2 genotyping and measurement of mood
and anxiety disorder symptoms. Because results for all three of the current SNPs may
have been affected by steroid hormones and neurosteroids, it may also be beneficial to
record the temporal proximity to menstruation in women (as a proxy measure of
progesterone, allopregnanolone, and estrogen) or to measure the levels of circulating
steroids in participants in addition to genotyping and administering behavioral measures
of impulsivity and self-aggression. Finally, the addition of functional neuroimaging
(particularly of the frontolimbic network) to future genetic association studies would be
helpful in increasing knowledge of gene-brain-behavior relationships.
Summary
COMT rs4680 was the only SNP related to both categorically and continuously
measured BPD as well as to impulse control and self-harm scores. However, COMT
heterozygotes often differing from the combined group of homozygotes (suggestive of
heterosis) presents difficulty in explaining, although some potential explanations were
proposed. In regard to the other SNPs, GABRA2 rs279871 was related to BPD, impulse
control, and self-harm scores, whereas SNCA rs356195 was only related to the former
two. Results in relation to GABRA2 rs279871 were entirely gender-specific, and COMT
rs4680 and SNCA rs356195 also yielded some gender-specific results. Gender-specific
results with COMT rs4680 may be explained by gender differences in COMT activity
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and dopaminergic function; gender-specific results with GABRA2 rs279871 may be
explained by gender differences in the levels of steroid hormones and neurosteroids as
well as by gender differences in the effects of neurosteroids and in the structure of brain
regions containing GABA-A receptor -2 subunits; and gender-specific results with
SNCA rs356195 may be explained by gender differences in the DA and -synuclein
systems. In conclusion, it appears that COMT, GABRA2, and SNCA may influence the
development of BPD and related traits and behaviors.
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APPENDIX A
IRB FORM
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APPENDIX B
BARRATT IMPULSIVENESS SCALE, VERSION 11 (BIS-11)
Instructions: For each item, please select the number corresponding to how often the
statement is true of you.
1 = Rarely/Never
2 = Occassionally
3 = Often
4 = Almost Always/Always
1. I plan tasks carefully
1

2

3

4

3

4

2

3

4

2

3

4

3

4

3

4

2

3

4

2

3

4

2. I do things without thinking
1

2

3. I make-up my mind quickly
1
4. I am happy go lucky
1

5. I don’t “pay attention”
1

2

6. I have “racing” thoughts
1

2

7. I plan trips well ahead of time
1
8. I am self-controlled
1

81
9. I concentrate easily
1

2

3

4

2

3

4

3

4

3

4

3

4

3

4

2

3

4

2

3

4

2

3

4

10. I save regularly
1

11. I “squirm” at plays or lectures
1

2

12. I am a careful thinker
1

2

13. I plan for job security
1

2

14. I say things without thinking
1

2

15. I like to think about complex problems
1
16. I change jobs
1
17. I act “on impulse”
1

18. I get easily bored when solving thought problems
1

2

3

4

3

4

19. I act on the spur of the moment
1

2
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20. I am a steady thinker
1

2

3

4

2

3

4

3

4

21. I change residences
1

22. I buy things on impulse
1

2

23. I can only think about one problem at a time
1

2

3

4

2

3

4

3

4

24. I change hobbies
1

25. I spend or charge more than I earn
1

2

26. I often have extraneous thoughts when thinking
1

2

3

4

27. I am more interested in the present than in the future
1

2

3

4

2

3

4

2

3

4

2

3

4

28. I am restless at theaters or lectures
1
29. I like puzzles
1
30. I am future oriented
1
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APPENDIX C
LIFE HISTORY OF AGGRESSION SELF-DIRECTED AGGRESSION SUBSCALE
(LHA SELF-DIRECTED AGGRESSION)
Instructions: Rate yourself on each of the following items using the rating system below.
Only rate actual behavior be it verbal and/or physical. Do not include in your ratings
thoughts not followed by any action or fantasies. For these questions it is important to
rate any events that have occurred over your lifetime (including your years as a teenager
and a young adult).
0 = Never Happened
1 = Only Happened Once
2 = Happened a Couple of Times (2-3)
3 = Happened Several Times (4-9)
4 = Happened Many Times (10+)
5 = Happened So Many Times I Couldn't Give a Number
How Many Times Would You Say You Did the Following Things Over the Course of
Your Life to DATE?
1. Deliberately tried to physically hurt yourself in anger or desperation.
0

1

2

3

4

5

2. Deliberately tried to end your life or kill yourself in anger or desperation.
0

1

2

3

4

5
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APPENDIX D
SELF-CONTROL SCALE (SCS)
Instructions: Using the following scale, please indicate how much each of the following
statements reflects how you typically are.
1 = Not Like Me At All
2
3
4
5 = Very Much Like Me
1. I have a hard time breaking bad habits.
1

2

3

4

5

2

3

4

5

3

4

5

4

5

2. I am lazy.
1

3. I say inappropriate things.
1

2

4. I never allow myself to lose control.
1

2

3

5. I do certain things that are bad for me, if they are fun.
1

2

3

4

5

6. People can count on me to keep on schedule.
1

2

3

4

5

3

4

5

3

4

5

7. Getting up in the morning is hard for me.
1

2

8. I have trouble saying no.
1

2
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9. I change my mind fairly often.
1

2

3

4

5

4

5

4

5

3

4

5

3

4

5

3

4

5

4

5

4

5

4

5

4

5

10. I blurt out whatever is on my mind.
1

2

3

11. People would describe me as impulsive
1

2

3

12. I refuse things that are bad for me.
1

2

13. I spend too much money.
1

2

14. I keep everything neat.
1

2

15. I am self-indulgent at times.
1

2

3

16. I wish I had more self-discipline.
1

2

3

17. I am good at resisting temptation.
1

2

3

18. I get carried away by my feelings.
1

2

3

19. I do many things on the spur of the moment.
1

2

3

4

5
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20. I don't keep secrets very well.
1

2

3

4

5

21. People would say that I have iron self-discipline.
1

2

3

4

5

22. I have worked or studied all night at the last minute.
1

2

3

4

5

4

5

23. I'm not easily discouraged.
1

2

3

24. I'd be better off if I stopped to think before acting.
1

2

3

4

5

3

4

5

3

4

5

25. I engage in healthy practices.
1

2

26. I eat healthy foods.
1

2

27. Pleasure and fun sometimes keep me from getting work done.
1

2

3

4

5

4

5

28. I have trouble concentrating.
1

2

3

29. I am able to work effectively toward long-term goals.
1

2

3

4

5

30. Sometimes I can't stop myself from doing something, even if I know it is wrong.
1

2

3

4

5
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31. I often act without thinking through all the alternatives.
1

2

3

4

5

3

4

5

3

4

5

3

4

5

3

4

5

3

4

5

32. I lose my temper too easily.
1

2

33. I often interrupt people.
1

2

34. I sometimes drink or use drugs to excess.
1

2

35. I am always on time.
1

2

36. I am reliable.
1

2
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